

**REMARKS****I. Explanation of Amendments to the Specification**

The amendments at pages 7, 14 and 16 correct obvious typographical errors. The paragraph beginning on page 7 was amended to correct the erroneous reference to the "peptides of SEQ ID NO: 3." As Figure 2 and the sequence listing demonstrate, SEQ ID NO: 3 is a nucleic acid sequence. In the foregoing amendment, the reference to peptides at page 8, lines 16 and 18, now refers to the "peptides of SEQ ID NO: 4" (SEQ ID NO: 4 is encoded by SEQ ID NO: 3). In addition, the amendment omits references to claims 14, 15 and 16 at page 14. The reference of "Swiss Mutation" at page 16 was a typographical error as evidenced by the references to "Swedish mutation" throughout the specification, for example at page 13, line 6-7, page 22, lines 15-17, page 41, lines 4-5 and page 74, line 7. These amendments do not add new matter to the specification.

In addition, the specification at page 32 describes tyrosine as a hydroxyl residue similar to serine. The correct statement should refer to threonine as a hydroxyl residue and this misstatement is corrected by the foregoing amendment. This was an obvious typographical error as tyrosine is described in the specification, at page 32, line 33 through page 33, line 1, as an aromatic residue. This amendment does not add new matter to the specification.

**II. The Rejection Under 35 U.S.C. § 102(e) Should be Withdrawn**

The Examiner rejected claims 1, 3 and 4 under 35 U.S.C. § 102(e), alleging that the claims are anticipated by U.S. Patent No. 6,319,689 (denoted herein as Powell *et al.*), as evidenced by Vassar *et al.* (*Adv. Drug Delivery Rev.* 54(12): 1589-1602, 2002). The Examiner alleged that Powell *et al.* discloses a polynucleotide that is 98.2% identical to SEQ ID NO: 3 and the polynucleotide sequence of Powell *et al.* encodes an aspartyl protease polypeptide that is 99.8% identical to SEQ ID NO: 4. The Examiner also alleged that Powell *et al.* teaches fragments of the polypeptides that retain aspartyl protease activity and variants with conservative substitutions that also retain aspartyl protease activity. In addition, the Examiner stated that Powell *et al.* discloses the complement of the polynucleotide and teaches hybridization of nucleic acid molecules to the polynucleotides and complements thereof. The Examiner also correctly noted that Powell *et al.* does not expressly teach that the aspartyl protease processes APP into amyloid beta, but the Examiner indicated that

Vassar *et al.* teaches that the claimed activity is an inherent property of the aspartyl protease. The Applicants traverse this rejection.

Anticipation requires that a prior art reference disclose a product (in this case polypeptides) that satisfies every limitation of a claim. Powell *et al.* does not teach every limitation of claim 1 or by extension, any of claims 3 or 4, because they depend from claim 1.

Part (a) of claim 1 specifies a polypeptide that comprises an amino acid sequence set forth in SEQ ID NO: 4. The Examiner agrees that the sequence in Powell *et al.* differs from SEQ ID NO: 4 (less than 100% identity), so Powell *et al.* does not anticipate the subject matter of part (a).

Part (b) of claim 1 specifies a polypeptide that comprises fragments of SEQ ID NO: 4 that exhibit aspartyl protease activity involved in processing APP into amyloid beta and include the aspartyl protease active site tripeptides DTG and DSG. Powell *et al.* differs from SEQ ID NO: 4 at position 130, which falls within the domain defined by active site tripeptides DTG and DSG. Thus, Powell *et al.* does not anticipate the subject matter of part (b).

Parts (c) of claim 1 specifies a polypeptide that comprises an amino acid sequence that is a conservative substitution variant of the polypeptides of parts (a) and (b), wherein the only amino acid differences are conservative substitutions otherwise the polypeptide sequence is identical to the sequences of parts (a) and (b). The genera of polypeptide defined by part (c) does not include the sequence taught by Powell *et al.* because the amino acid sequence disclosed in Powell *et al.* has a Glu at position 130, while SEQ ID NO: 4 has a Val at position 130. A substitution of Val for Glu is not a conservative substitution, as Glu is an acidic residue and Val is an aliphatic residue. (Likewise, Powell *et al.*, does not anticipate the polypeptide of claim 19 with aspartyl protease activity, which is identical across its length to a sequence in SEQ ID NO: 4).

Vassar *et al.* is a review article that discusses the clinical significance of BACE1 (also known as  $\beta$ -secretase or Asp2). The amino acid sequence provided in Fig. 2 of Vassar *et al.* teaches the amino acid sequence of SEQ ID NO: 4 of the present invention and not the amino acid sequence taught in Powell *et al.* Accordingly, the amino acid sequence taught in Vassar *et al.* has a Val at position 130. The difference in the Powell *et al.* and

Vassar *et al.* amino acid sequences is within the domain defined by the active site tripeptides. Therefore, Vassar *et al.* does not inherently teach an activity for the Powell *et al.* protein.

Claim 4 specifies that the polypeptide lacks a transmembrane domain. The present application explains that the full length Asp2 protein has a transmembrane domain near its C-terminus. This discovery would not have been expected from other aspartyl proteases that had been described in the art, such as renin, pepsinogen, pepsin, and cathepsin D, which did not reportedly have transmembrane domains.

Powell *et al.* purports to disclose a deduced amino acid sequence of a protein called Asp2, but Powell *et al.* fails to teach or suggest that Powell's Asp2 has a transmembrane domain at all, and certainly does not teach to remove a transmembrane domain for any reason. Likewise, Powell *et al.* does not by chance teach any specific Asp2 fragment that lacks the region identified by the Applicants as a transmembrane domain of Asp2 in the present application. Thus, Powell *et al.* does not anticipate the subject matter of claim 4.

Thus, claims 1, 3 and 4 do not read on subject matter disclosed or suggested by Powell *et al.*, and the rejection for anticipation should be withdrawn.

### **III. Rejection Under 35 U.S.C. § 112, First Paragraph for Lack of Adequate Written Description Should be Withdrawn**

The Examiner rejected claims 1, 3, 4 and 16-19 under 35 U.S.C. § 112, first paragraph, alleging the specification fails to describe the claimed subject matter in such a way to reasonably convey to one of skilled the art that Applicants were in possession of the invention at the time of filing. The Applicants traverse this rejection.

At the outset, Applicants request that independent claims 17-19 be examined on their merits rather than be lumped with claim 1. These claims contain limitations of sequence identity to a reference sequence. As such, the Examiner's concern as to the structure and activity of variants is misplaced.

The main basis for rejection appears to be an assertion that the specification does not adequately describe all of the variants embraced by independent claim 1.

Part (a) of claim 1 specifies that the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 4. Due to the well known degeneracy of the genetic code,

SEQ ID NO: 4 defines the structure of the entire genus of polynucleotides that encode it, for a person of ordinary skill.

Part (b) of claim 1 recites fragments of (a) that include the aspartyl protease active site tripeptides DTG and DSG and exhibit aspartyl protease activity involved in processing APP into amyloid beta. There are only one DTG and one DSG in SEQ ID NO: 4, so the genus defined by part (b) is also well defined by SEQ ID NO: 4. Fragments that retain aspartyl protease activity are described at page 30, lines 3-21. Aspartyl protease activity involved in processing APP into amyloid beta is described in the specification at page 1, lines 25-27, page 40, lines 25-27, and pages 55-58 (Example 7). Fragments that include the aspartyl protease active site tripeptides DTG and DSG are described in the specification at page 30, lines 9-19. The application also provides aspartyl protease assays and substrates for the enzyme. Thus, the specification adequately describes the subject matter of part (b).

Part (c) of claim 1 recites that the polypeptide is a conservative substitution variant of (a) or (b), wherein the conservative substitution variant is identical to (a) or (b) except for conservative substitutions and is encoded by a nucleic acid molecule that hybridizes under stringent conditions to complement of SEQ ID NO: 3. In addition, the conservative substitution variant exhibits aspartyl protease activity involved in processing APP into amyloid beta. Conservative substitutions are described in the specification at page 32, line 26, through page 33, line 2.

The limitation specifying that the polypeptide is encoded by nucleic acid molecule that hybridizes under the following stringent hybridization conditions to the complement of SEQ ID NO: 3 (i) hybridization at 42°C in a hybridization buffer comprising 6x SSC and 0.1% SDS, and (ii) washing at 65°C in a wash solution comprising 1x SSC and 0.1% SDS reduces the number of variants encompassed by the genus. Example 9 of the Patent Office's Written Description Guidelines Training Materials provides a hypothetical invention involving nucleic acid sequence that hybridize under highly stringent condition to the complement of a disclosed sequence and the nucleic acid encodes a protein with a recited activity. The Patent Office's opinion regarding such a claim is that one of skill in the art would not expect substantial variation among the species encompassed by the claim because the recited hybridization conditions yield structurally similar nucleic acids. Therefore, the disclosed sequences are considered a representative number of species in view of the

structural and functional requirements of the claim and therefore the genus of polypeptides is adequately described. The further limitation that the differences are conservative substitutions notably reduces the species encompassed by the claimed genus of polypeptides of part (c). The Patent Office's analysis of the written description requirement in the hypothetical does not concern itself with whether the specification provided specific guidance about specific changes at specific positions in the sequence because the genus is sufficiently described by the hybridization limitation, the reference sequence and the biological activity. Or stated differently, the combination of limitations used by the Applicants has been recognized by the Patent Office to provide sufficient specificity and limit variability enough to satisfy the written description requirement.

Claims 16-19 are directed to additional variant polypeptides, which are biologically active aspartyl proteases with a valine at a position that corresponds to position 130 of SEQ ID NO: 4. In claim 16, the polypeptide is encoded by a nucleic acid that hybridizes to SEQ ID NO: 3 under stringent wash conditions. According to Example 9 of the Written Description Guidelines described above, claim 16 is adequately described by the specification. In claim 17, the polypeptide is encoded by a nucleic acid which is identical across its length to the sequence set forth in SEQ ID NO: 3. In claim 18, the polypeptide is encoded by nucleic acid which is identical to a sequence set forth as SEQ ID NO: 3, and claim 19 is directed to a polypeptide comprising an amino acid sequence which is identical across its length to a sequence in SEQ ID NO: 4. Claims 17, 18 and 19 are adequately described in the specification for the same reasons that polypeptides of claim 1(a) or 1(b) are adequately described.

The "Summary of Invention" section of the patent application contemplates and describes polypeptides having aspartyl protease activity and characterized by a first tripeptide DTG and a second tripeptide DSG and 100-300 amino acids in between these tripeptides or "special amino acids." (See, *e.g.*, pp. 3-9; see also p. 26, lines 23-27 of the detailed description.) In SEQ ID NO: 4, these tripeptides occur at positions 93-95 and 289-291. References to these signature sequences, which help define the protease active site of Asp2, are incorporated into the claims to clarify that the claimed polypeptide fragments do not encompass short peptides lacking an active site. The minimum active site can be precisely defined using the activity assays taught in the applications, *e.g.* at pages 74-75. The

application also provides significant guidance with regard to signal peptide and propeptide domains of the full length Asp2 polypeptide that are not required for activity. For example, the domains of SEQ ID NO: 4 are defined by amino acid number at page 19, line 24 through page 20, line 3 as follows: the signal sequence spans residues 1-21, the pre-propeptide spans residue 22-45, the propeptide extends to residue 57, the transmembrane domain spans residues 455-477, the cytoplasmic domain spans residues 478-501. The specification identifies a putative alpha helical spacer region that spans residues 420-454 (located between the catalytic domain and the transmembrane domain). (See page 21, line 2-3) This region has cysteine residues that may be implicated in disulfide bonding of the full length or transmembrane deleted Asp2 protein.

In view of the foregoing remarks, claims 1, 3, 4 and 16-19 are adequately described in the specification. Applicants request that the rejection under 35 U.S.C. § 112, first paragraph, for lack of adequate written description be withdrawn.

**IV. Rejection Under 35 U.S.C. § 112, First Paragraph for Lack of Enablement Should be Withdrawn**

The Examiner rejected claims 1, 3, 4 and 16-19 under 35 U.S.C. § 112, first paragraph alleging that the specification does not enable the full scope of the claims. In particular, the Examiner stated that the specification does not reasonably provide enablement for polypeptide variants. Applicants traverse this rejection.

As with the written description rejection, the Applicants request independent evaluation of claims 17-19 because the sequence identity limitation of these claims render moot many of the issues raised with respect to “variants.”

The specification provides a method for identifying variant polypeptide and polypeptide fragments of SEQ ID NO: 4 (see Examples 1 and 2 of the specification; pages 41-47). In particular, the specification teaches how to screen databases for nucleic acid sequences encoding polypeptides comprising the hallmark aspartyl protease active site tripeptides, and to screen human cDNA libraries once the sequences are identified. The polynucleotide can then be cloned from natural sources. Once the nucleic acid sequences of the invention are identified, the specification teaches how to recombinantly express the polypeptides of the invention using expression vectors and host cells (see page 34, line 25 through page 38, line 4 through page 39, line 29). In addition, the specification teaches how

to recover and purify polypeptides from tissues, cultured cells or recombinant cell cultures (see page 34, lines 8-24). The specification also teaches methods for obtaining polynucleotide variants by mutating native nucleotide sequences, such as oligonucleotide-directed mutagenesis (see page 32, lines 3-25).

In addition, the specification teaches assays to determine if the polypeptide retains aspartyl protease activity involved in processing APP into amyloid beta (Example 12, pages 74-75). The amino acid sequences that serve as substrates for an enzyme involved in APP processing are taught in the application and are known in the art. (See Haass *et al.* Cell 75: 1039-1042, 1993; Exhibit A and Citron *et al.*, Neuron 14: 661-70, 1995, Exhibit B). The specification teaches that active fragments and variants of the Asp2 aspartyl proteases include the aspartyl protease active site tripeptides DTG and DSG; and these tripeptides are necessary for the fragment to retain activity (page 30, lines 9-14 of the specification).

The specification adequately enables polypeptide fragments and conservative substitution variants of the amino acid sequence of SEQ ID NO: 4. The Applicants disclosed two amino acid sequences (SEQ ID NOS: 6 and 8) which are at least 95% identical to the amino acid sequence of SEQ ID NO: 4. Example 12 demonstrates that, in addition to having 95% identity to SEQ ID NO: 4, the Asp2 polypeptide of SEQ ID NO: 6 possesses APP processing activity similar to Asp2 polypeptide of SEQ ID NO: 4. The Applicants also disclosed the amino acid sequence of murine Asp2(a) as SEQ ID NO: 8, which is greater than 95% identical to SEQ ID NO: 4. Further, in Example 3 the Applicants provide a working example which enables one of skill in the art to isolate Asp2 polypeptides which have 95% identity to SEQ ID NO: 4 from a cDNA library. (See page 41, line 1 through page 49, line 4). Polypeptides that encoded by a nucleic acid sequence that is highly similar ( *e.g.* 95% identical) to another nucleic acid sequence are expected to hybridize under stringent conditions.

In addition, the specification adequately enables polynucleotides that hybridize to the complement of SEQ ID NO: 3 under the recited stringent hybridization conditions. Methods of detecting polynucleotides that hybridize to a particular nucleotide sequence are well known in the art. The claims require that the polynucleotide hybridize under stringent conditions, and under these conditions one of skill in the art would not expect

substantial variation among the species encompassed with the scope of the claim (see page 36 of the U.S. Patent and Trademark Office Revised Written Description Guidelines).

The claims specifically define the differences in the variant polypeptide sequence as conservative substitutions. Groups of amino acids with similar physiochemical properties are well known in the art (See Stryer pages 18-21, attached hereto as Exhibit C). The term is also recognized by the U.S. PTO and is common in the art (See MPEP § 2144.08). This claim limitation significantly reduces the number of variant polypeptides encompassed by the structural limitation of the claims, and increases the percentage that would be shown, through routine screening, to retain enzymatic activity (the functional limitation of the claims). Contrary to the Examiner's basis for rejection, the specification, in view of the recited claim limitations, provides adequate guidance as to the common features of the claimed genus and guidance as to which regions of the polypeptides of the invention may be conserved to maintain aspartyl protease activity.

The Examiner asserted that the specification does not provide the structural requirements of the amino acid sequences encompassed by the claims and it is unpredictable which variations meet the limitations of the claims. The structural components necessary for aspartyl protease activity are taught in the specification, and the claimed fragments are required to have the aspartyl protease active site tripeptides DTG and DSG. The specification, at page 25, lines 25-30, teaches that aspartyl proteases possess a two domain structure which folds to bring two aspartyl protease residues into proximity of the active site and the active site is embedded in the short tripeptide motifs DTG and DSG. Therefore, small or inactive fragments and variants are not encompassed by the claims. The structural and functional limitations in the claim provide the necessary guidance for one of skill in the art to make and use the polynucleotides of the present invention. Moreover, the assays provided in the application allow one to determine whether any particular polypeptide variant is active using only routine screening, and routine screening does not constitute "undue experimentation" under the law.

Furthermore, the specification describes how to make fragments of SEQ ID NO: 4 with the transmembrane domain deleted. In addition, Example 8 (pages 58-63) demonstrates that the transmembrane deleted fragments are active. The specification also teaches that the polypeptide of SEQ ID NO: 4 has a pre-propeptide that spans residues 22-45



and a propeptide that spans residues 46-57. (See page 19, lines 26-30). One of skill in the art understands that these peptide may be deleted to create an active fragment. The specification also teaches assays for measuring the aspartyl protease activity of the fragments. For example, a novel cell line for measuring processing of APP into amyloid beta is taught at page 40, lines 25-31. These cells can be transfected with a polynucleotide of the invention that expresses the claimed fragment. At pages 51-57, the Applicants teach human cell lines that process APP which provide a means for screening for APP processing activity. Production of amyloid beta peptide in culture can be measured by EIA as described at pages 53-54. Example 12 (pages 74-75), provides cell-free assays using synthetic peptide substrates to measure the aspartyl protease activity of the fragments.

The Patent Office cites the Federal Circuit's *Wands* decision and cites the "*Wands* factors," and the Applicants agree that these principles govern an enablement analysis. However, these principles have been misapplied.

*Wands* involved screening of large numbers of hybridomas to identify specific hybridomas that fell within the claim limitations. Because the patentee in *Wands* provided sufficient guidance to make and screen the hybridomas and presented working examples, that the enablement requirement was fulfilled. *In re Wands*, 858 F.2d 731, 740 (Fed. Cir. 1988). *In re Wands* does not hold that a specific number of working examples is required. In reaching a decision, the court in *Wands* considered that the inventor's disclosure provides considerable direction and guidance on how to practice the invention and presents working examples. *Id.* at 740. This fact, coupled with the high level of skill in the biotechnology arts, rendered the invention enabled, according to the Court. *Id.* Although a considerable amount of work may have been required to do the making and screening, such experimentation is routine, not "undue," according to Federal Circuit's decision in *Wands*.

In the present application, the claims of the application are directed to a genus of polypeptides with limited variation from a wild-type protease sequence, and required to retain the protease activity. The specification fully discloses methods to make the claimed polypeptides and methods to determine whether these polypeptides exhibit protease activity toward substrates (also taught in the application). Similar to *Wands*, the invention provides a composition that cleaves (rather than binds) to a specific target, with the target cleavage identified using well-known screening methods. In the many years that have passed since the

invention at issue in *Wands*, when the level of skill was already considered high, the level of skill in the rapidly advancing arts of DNA and protein manipulation, synthesis, and screening are clearly very high.

In fact, the making and screening required by the present invention (polypeptide identification and enzymatic testing) is much simpler and faster – more routine -- than the making and screening of hybridomas and antibodies set forth in the facts of *In re Wands*, which the Court said was not undue experimentation. Experimentation, even if extensive, is not necessarily undue if it is routine in the art (*In re Wands*, 858 F.2d 731 (Fed. Cir. 1988)).

Notwithstanding these favorable considerations relative to *Wands*, and the fact that polypeptide identification, production and screening is much more routine than *Wand's* hybridoma synthesis, monoclonal production, and monoclonal screening, the Examiner for this case reaches the opposite conclusion from the conclusion drawn by the Federal Circuit in *Wands*. Notwithstanding the lip-service paid to *Wands*, the Examiner refuses to recognize that the application teaches methods for making polypeptides of varying sequence using techniques common in the art such as recombinant expression, and teaches assays, many *in vitro*, by which the polypeptides and fragments can be routinely screened.

In addition, the Examiner cited to Mickle *et al.* (*Med. Clin. North Amer.* 84(3): 597-607, 2000), Voet *et al.* (*Biochemistry*, 1990 John Wiley & Sons, pgs. 126-129 and 228-234) and Yan *et al.* (*Science* 290: 523-527, 2000) to demonstrate that a single amino acid change can alter the function of a protein. Mickle *et al.* describes point mutations that are thought to be involved in the pathogenesis of cystic fibrosis. Voet *et al.* teaches that a single amino acid substitution thought to be involved in the pathogenesis of sickle cell anemia. Yan *et al.* teaches that alteration of two amino acids in a protein can change the receptor to which the protein binds. Each of these reports are isolated examples, and none of these reports were specifically directed to the question of what percentage of mutations in their respective proteins are silent versus activity-destroying. The authors and editors presumably had little interest in publishing about silent mutations. The identification of point mutations that have pathogenic implications is of great interest to the medical and research community and are published, but the studies have no probative value for assessing the likelihood of success at generating active variants. As described above, the present

specification provides nucleic acid sequences encoding the human and murine Asp2 amino acid sequences and therefore one of skill in the art can determine the conserved residues using simple computer alignment programs, which are referred to within the specification. In addition, the cited articles are not relevant because the present specification teaches the protease activity of the encoded polypeptides and the claims are directed to polypeptides with minor sequence variations that retain protease activity. The function of the variant polypeptides may be determined by routine screening for cleavage of APP as described in the specification.

For the foregoing reasons, the specification provides reasonable enablement of claims 1, 3, 4 and 16-18. Therefore, Applicants request that the rejection under 35 U.S.C. § 112, first paragraph for lack of enablement be withdrawn.

**V. Declaration of Michael Bienkowski, Ph.D.**

Submitted herewith (as Exhibit D) is a Declaration of Michael Bienkowski, Ph.D., that was submitted during prosecution of related U.S. patent applications.

**VI. Obviousness-Type Double Patenting Rejections**

Claims 1, 3, 4 and 16-19 were rejected under the judicially created doctrine of obviousness-type double patenting in view of the following patents: U.S. Patent Nos. 6,913,918, 6,825,023 and 6,828,117. In addition, claims 1, 3, 4 and 16-18 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting in view of the co-pending patent application no. 10/940,867.

Applicants request that these double patenting rejections be held in abeyance until there is an indication of allowable subject matter. At that time, Applicants will consider filing appropriate disclaimer(s). It is premature to disclaim term before the scope of an allowable claim is clear.

**VII. Related Applications**

On page 7 of the Office Action, the Examiner requested that the Applicants provide an updated listing of the related patent applications such as the listing provided with the Information Disclosure Statement dated April 5, 2005. Submitted herewith, as Appendix E, is an updated list of issued U.S. patents and pending U.S. patent applications that are related to the above-identified application. The related applications claim priority to U.S.

provisional applications 60/101,594 and 60/155,493, U.S. application 09/404,133 (abandoned) and U.S. application 09/668,314. One or more of the related applications may contain claims that are similar in scope or content to claims of the present application. Copies of these applications are not enclosed, but are pending in the U.S. Patent Office and should be available to the Examiner.


During the course of prosecution of these applications, different examiners have raised a variety of rejections under 35 U.S.C. §102, §103, §112, first and second paragraphs, and double patenting. Upon request, the Applicants will provide the Examiner with copies of office actions and/or responses filed for the related applications. The Examiner is invited to contact the undersigned if further explanation of the patent family is necessary.

**CONCLUSION**

In view of the foregoing remarks, Applicants believe claims 1, 3, 4 and 16-18 are in condition for allowance and early notice thereof is solicited.

Dated: March 28, 2007

Respectfully submitted,

By   
Sharon M. Sintich

Registration No.: 48,484

MARSHALL, GERSTEIN & BORUN LLP  
233 S. Wacker Drive, Suite 6300  
Sears Tower  
Chicago, Illinois 60606-6357  
(312) 474-6300  
Attorney for Applicant

# Cellular Processing of $\beta$ -Amyloid Precursor Protein and the Genesis of Amyloid $\beta$ -Peptide

## Minireview

Christian Haass and Dennis J. Selkoe

Center for Neurologic Diseases

Harvard Medical School

Brigham and Women's Hospital

Boston, Massachusetts 02115

In 1907, Alois Alzheimer described a novel brain disease that principally affects late middle-aged and older humans and results in a progressive and ultimately fatal loss of mental capacity, particularly recent memory. This disorder, later called Alzheimer's disease (AD), is defined by characteristic neuropathological lesions in brain regions important for intellectual function. The only invariant pathological change is the formation of extracellular amyloid plaques in the cerebral and limbic cortices and chemically similar amyloid deposits in the walls of meningeal and cerebral blood vessels. Other structural changes found in AD brain, including the intraneuronal neurofibrillary tangles, are not restricted to AD but also occur in numerous etiologically diverse neurodegenerative diseases, and they are sometimes sparse in AD itself.

### The Amyloid $\beta$ -Peptide Plays an Early Role in the Pathogenesis of AD

The major proteinaceous component of the vascular and plaque amyloid deposits, the hydrophobic 39–43 residue amyloid  $\beta$ -peptide (A $\beta$ ), is proteolytically derived from an integral membrane protein, the  $\beta$ -amyloid precursor protein ( $\beta$ APP; Figure 1) that is encoded by a gene on human chromosome 21 (Kang et al., 1987). Importantly, patients with trisomy 21 (Down's syndrome) develop neuropathological changes indistinguishable from those of AD, but starting at a very early age. The finding that an extra copy of the  $\beta$ APP gene invariably leads to typical AD pathology that begins with amyloid plaque formation supports the hypothesis that the metabolism of  $\beta$ APP into A $\beta$  may play a crucial role in the pathogenesis of the disease. Furthermore, synthetic A $\beta$ s have been shown to produce toxic effects on cultured neurons (Yankner et al., 1990), although the cellular and molecular mechanisms of A $\beta$ -associated neurotoxicity remain controversial. Perhaps the strongest evidence for a pathogenic role of  $\beta$ APP emerges from the discovery that some cases of autosomal dominant AD are strongly linked to missense mutations in the  $\beta$ APP gene, specifically within and immediately flanking the A $\beta$  sequence (summarized by Hardy, 1992). For these reasons, this review will focus on the complex cellular processing of  $\beta$ APP and particularly on the recent discovery that A $\beta$  is generated continuously by a physiological mechanism.

### Conventional Secretory Processing of $\beta$ APP Prevents the Generation of A $\beta$

The primary structure of  $\beta$ APP closely resembles a cell-surface receptor (Figure 1) with a signal sequence, a large extramembranous N-terminal region, a single transmembrane domain, and a small cytoplasmic C-terminal tail (Kang et al., 1987). A $\beta$  represents only a small fragment

of  $\beta$ APP, and proteolytic processing of the precursor results in the formation of this peptide. The last 11–15 amino acids of A $\beta$  are located within the transmembrane domain (Figure 1), presumably protecting it from proteolytic cleavage. Moreover, A $\beta$  generation is complicated by the fact that normal secretory processing of  $\beta$ APP (Weidemann et al., 1989) results in a cleavage of the precursor at amino acid 16 within A $\beta$  (Esch et al., 1990). This scission, made by an unidentified enzyme designated  $\alpha$ -secretase, leads to the secretion of the large soluble ectodomain of  $\beta$ APP (APP<sub>s</sub>) and the retention of the small 10 kd C-terminal fragment within the membrane (Figure 2A). The  $\alpha$ -secretase-mediated cleavage of  $\beta$ APP can apparently occur at the cell surface (Sisodia, 1992; Haass et al., 1992a) or intracellularly (Sambamurti et al., 1992). Thus, conventional secretory processing of  $\beta$ APP precludes the formation of A $\beta$ . Based on these data, it has been widely assumed that only aberrant processing under pathological conditions could lead to the formation of A $\beta$  and its release from the cell membrane.

### Endosomal-Lysosomal Processing of $\beta$ APP Leads to Potential A $\beta$ Precursors

During the last year, evidence has accumulated that only a minority of  $\beta$ APP molecules are actually processed by this secretory pathway. C-terminal fragments of  $\beta$ APP were identified in cultured cells (Golde et al., 1992; Haass et al., 1992a) or brain tissue (Estus et al., 1992) that contained the complete A $\beta$  sequence and could thus serve as potential degradative intermediates for A $\beta$  formation. These fragments were found to be stabilized by leupeptin,





Figure 1. The Primary Structure of  $\beta$ APP

The vertical lines represent the single transmembrane domain, and the open box represents the A $\beta$  peptide. The lysine and methionine residues that are underlined are substituted by asparagine and leucine, respectively, in the case of the double missense mutation found in a Swedish family with autosomal dominant AD. The horizontal boxes and lines below the A $\beta$  sequence represent peptides that have been found to be secreted by a variety of tissue culture cells. The major species begins at Asp-1, whereas minor peptides begin at Val(-3), Ile(-6), Phe-4, and Glu-11. The stippled box corresponds to p3, which starts at Leu-17 (hatched segment) or at Val-18. The C-terminus of secreted A $\beta$  also shows heterogeneity, with a major species ending at residue 40.



**Figure 2. Known Cellular Processing Pathways of βAPP**  
(A) Conventional secretory processing of βAPP. (B) Endosomal-lysosomal processing of βAPP. (C) Proteolytic generation of Aβ and p3. Arrowheads designated α and β indicate the sites of cleavage of βAPP utilized by unidentified proteases designated α-secretase and β-secretase, respectively. The arrowhead within the transmembrane region of βAPP indicates the sites of the Aβ C-terminal cleavage, again effected by an unknown protease.

ammonium chloride, or chloroquine, agents known to inhibit endosomal-lysosomal proteases. Such results led to the proposal that βAPP could also be processed in an endosomal-lysosomal pathway. However, it is not clear whether some of these fragments may initially be made within the Golgi or at the cell surface and then accumulate within the lysosome, where they could be subjected to further processing and degradation. Surface biotinylation and antibody binding experiments on living cells revealed that full-length βAPP can be reinternalized from the cell surface in an apparent coated pit-mediated pathway (Haass et al., 1992a). Indeed, full-length βAPP and the 10 kD C-terminal fragment have been found within isolated clathrin-coated vesicles (Nordstedt et al., 1993). Furthermore, isolation of late endosomes-lysosomes from leupeptin-treated cells directly demonstrated that full-length βAPP, the 10 kD C-terminal fragment, and a range of slightly larger C-terminal fragments of βAPP containing the intact Aβ sequence accumulate within lysosomes (Haass et al., 1992a). Taken together, these observations indicate that some full-length βAPP molecules are reinternalized from the cell surface and targeted, together with the 10 kD and probably other C-terminal fragments, to lysosomes for final degradation (Figure 2B). In addition to this reinternalization pathway, a pathway that targets βAPP from the trans-Golgi network directly to endosomes and lysosomes could exist.

#### **Normal Cellular Processing of βAPP Leads to the Secretion of Aβ**

The description of a normal processing pathway for βAPP that generates Aβ-bearing fragments under physiological

conditions suggested that aberrant processing of βAPP might not be necessary to generate Aβ. This concept has now been validated by the unexpected discovery that Aβ is normally secreted into the media of a wide array of cultured cells that express βAPP (Haass et al., 1992b; Seubert et al., 1992; Shoji et al., 1992; Busciglio et al., 1993). In such conditioned media, peptides of 4 kD (Aβ) and 3 kD (p3) were identified by immunoprecipitation with antibodies to Aβ (Figure 2C) (Haass et al., 1992b; Shoji et al., 1992; Busciglio et al., 1993). Radiosequencing indicates that βAPP proteolysis normally yields a heterogeneous population of Aβ and closely related peptides (Figure 1). Within the 4 kD range, the major peptide appears to be identical to Aβ starting at Asp-1 (Haass et al., 1992b; Seubert et al., 1992). Additional peptides have been identified in minor amounts that start at Val(-3), Ile(-6), Glu-11, or Phe-4 (Haass et al., 1992b) (Figure 1). In addition to this N-terminal heterogeneity, the C-termini of Aβ in culture medium also vary considerably (Dovey et al., 1993). In the 3 kD range, the peptide begins at or immediately adjacent to the conventional α-secretase cleavage site (Figure 1), suggesting that this fragment arises from the 10 kD C-terminal peptide (Haass et al., 1992b) (Figure 2C, left). These data suggest that the C-terminal cleavages creating the Aβ and p3 peptides are mediated by similar, if not identical, proteases. This C-terminal Aβ cleavage should create an ~7 kD βAPP C-terminal fragment (p7 in Figure 2C). Indeed, small amounts of such a fragment can be detected in lysates of cells transfected with a βAPP cDNA (C. H. and D. J. S., unpublished data). The N-terminal cleavage generating p3 is thus probably made by α-secretase, whereas the N-terminal cleavage generating Aβ appears to be mediated by a highly sequence-dependent protease (Citron et al., 1992; M. Citron and D. J. S., unpublished data) distinct from α-secretase, which has been shown to cleave βAPP in a sequence-independent manner (Sisodia, 1992). This β-secretase cleavage should result in a truncated species of APP<sub>3</sub>; indeed, such a form of APP<sub>3</sub> terminating just before the Aβ region has recently been detected in the media of cultured cells (Seubert et al., 1993) (Figure 2C, right).

Importantly, Aβ has been detected not only in the supernatants of cultured cells but also in normal body fluids, e.g., in human cerebrospinal fluid (Seubert et al., 1992; Shoji et al., 1992). An Aβ-immunoreactive species has been detected in human serum (Seubert et al., 1992), although its chemical identity has not yet been established. These findings indicate that *in vitro* production of Aβ reflects βAPP processing *in vivo*.

The observation that Aβ is normally produced by cultured cells provides a dynamic model system in which one can examine the detailed molecular mechanisms leading to Aβ. Heretofore, Aβ had only been obtained, laboriously and in small quantities, from insoluble amyloid deposits of postmortem human brain. As noted above, several missense mutations in the βAPP gene have been identified to date in patients with early-onset familial AD. A key step toward understanding the pathogenesis of AD will be to clarify the effect of these mutations on βAPP processing. So far, no obvious changes in the conventional secretory

processing of these mutant  $\beta$ APP molecules in vitro have been documented. However, at least one of these mutations, one that was identified in a Swedish family (Mullan et al., 1992) (Figure 1), results in a striking 5- to 8-fold increase in secretion of A $\beta$  in vitro (Citron et al., 1992; Cai et al., 1993). This increase in A $\beta$  production is due to a methionine to leucine switch at the N-terminal cleavage site of A $\beta$ , a substitution that apparently increases the affinity of the substrate for the  $\beta$ -secretase. These findings provide a clear link between a familial AD genotype and the generation of the AD neuropathological phenotype. However, another missense mutation in the  $\beta$ APP gene at codon 717 (4–6 residues beyond the usual C-terminus of A $\beta$ ) has so far not been shown to result in an obvious increase of A $\beta$  production (Cai et al., 1993). Whereas this mutation and others at the same codon (Hardy, 1992) might not affect the quantity of A $\beta$ , they could potentially result in longer, more readily aggregating peptides. It is known that additional amino acids at its C-terminus may enhance the aggregation of A $\beta$  in vitro (Jarrett and Lansbury, 1993).

In addition to the several known missense mutations in  $\beta$ APP, genes linked to the familial AD phenotype have been localized to chromosome 14 (e.g., Schellenberg et al., 1992) and chromosome 19 (Strittmatter et al., 1993). The responsible gene on chromosome 14 has not yet been identified, but one might speculate that it could be involved in regulating  $\beta$ APP expression or processing or the metabolism of A $\beta$  itself, since the families linked to chromosome 14 have a very early and severe  $\beta$ -amyloidotic phenotype. On chromosome 19, the gene encoding apolipoprotein E shows segregation of the  $\epsilon$ 4 allele with late-onset familial AD (Strittmatter et al., 1993). How the normally occurring  $\epsilon$ 4 polymorphism, which results in a single amino acid substitution in apolipoprotein E, predisposes subjects to AD remains to be determined. One hypothesis suggests that apolipoprotein E might bind to and serve as a carrier of A $\beta$  in vivo. These findings and others clearly indicate that familial AD is genetically heterogeneous. It appears that mutations or polymorphisms in a variety of gene products will ultimately be shown to lead to progressive cerebral  $\beta$ -amyloidosis and AD.

#### **Mechanism of A $\beta$ Production and Regulation**

Little is currently known about the cellular mechanisms that allow A $\beta$  generation. Interestingly, A $\beta$  has thus far not been detected intracellularly (Haass et al., 1992b, 1993; Shoji et al., 1992). The complete inhibition of A $\beta$  generation by brefeldin A suggests that transport of  $\beta$ APP through the Golgi is a prerequisite for A $\beta$  production (Haass et al., 1993). A $\beta$  formation is not inhibited by leupeptin (Shoji et al., 1992; Haass et al., 1993; Busciglio et al., 1993), and A $\beta$  has not been found in isolated lysosomes (Haass et al., 1993). However, agents that interfere with pH gradients in vesicular compartments (NH<sub>4</sub>Cl, chloroquine, monensin) markedly inhibit A $\beta$  production in most cell types studied (Shoji et al., 1992; Haass et al., 1993), suggesting that an acidic compartment is necessary for A $\beta$  generation. It is therefore hypothesized that A $\beta$  might be generated in late Golgi vesicles or in early endosomes. With regard to the latter, it is interesting to note that a truncated  $\beta$ APP con-

struct that lacks the cytoplasmic tail still allows the production of 4 kd peptides, although the large majority of these peptides do not start at Asp-1 of A $\beta$  (Haass et al., 1993). This result suggests that the cytoplasmic domain of  $\beta$ APP (which contains the NPXY consensus sequence for clathrin-mediated endocytosis) may play a role in targeting the precursor to the subcellular compartment involved in A $\beta$  generation and that reinternalization from the cell surface may favor formation of the peptide.

Whereas all  $\beta$ APP-expressing cells examined to date process some precursor molecules into A $\beta$ , recent data show that the metabolism of the precursor appears to be a highly regulated process that can be influenced by extracellular signals and intracellular second messengers. These results could potentially be important for the treatment of AD, because they may offer one pharmacological approach to partially inhibiting the production of A $\beta$ . The activation of protein kinase C (PKC) by phorbol esters or certain first messengers can increase the secretion of APP<sub>s</sub> (e.g., Nitsch et al., 1992). However, site-directed mutagenesis of potential phosphate acceptor residues in the cytoplasmic domain demonstrates that this PKC-mediated effect does not involve enhanced phosphorylation of the  $\beta$ APP molecule itself; indeed,  $\beta$ AAP is basally phosphorylated solely on its ectodomain (A. Hung and D. J. S., in press). Thus, a distinct protein activated by PKC-mediated phosphorylation is likely to be implicated in  $\beta$ APP secretory processing, for example,  $\alpha$ -secretase itself or a protein involved in the trafficking of vesicles that contain  $\beta$ APP. Coincident with the enhancement of secretion of APP<sub>s</sub>, PKC activation consistently and substantially decreases A $\beta$  formation. This down-regulation is observed after stimulation of the phospholipase C–PKC-linked muscarinic m1 receptor (Hung et al., 1993) or after direct phorbol ester treatment (Hung et al., 1993; Buxbaum et al., 1993).

Based on these data, alternative cellular pathways appear to determine whether  $\beta$ APP is destined for an amyloidogenic or nonamyloidogenic fate. PKC activation may increase the likelihood that  $\beta$ APP is cleaved by  $\alpha$ -secretase or else it may target  $\beta$ APP into a cellular compartment that produces lower amounts of A $\beta$ .

#### **Implications for the Potential Therapy or Prevention of AD**

The discovery of A $\beta$  generation by cultured cells provides a model system capable of identifying and characterizing pharmacological agents that can down-regulate A $\beta$  production. Furthermore, the ability to quantitate soluble A $\beta$  in biological fluids could lead to a cerebral spinal fluid or plasma assay to monitor A $\beta$  before and during the course of the disease. Chronically lowering A $\beta$  levels in brain, cerebral spinal fluid, serum, or some combination could provide a critical means of slowing the generation of the neuropathological lesions of AD. Decreasing the production of other amyloidogenic precursor proteins has already proven successful in slowing or halting certain potentially lethal amyloid deposition diseases in humans. Further efforts to identify the precise cellular pathway that generates A $\beta$  and to characterize the responsible proteases may provide a particularly attractive route to diminishing the cerebral amyloid burden during aging and in AD.

## References

- Busciglio, J., Gabuzda D., Matsudeira, P., and Yankner, B. (1993). *Proc. Natl. Acad. Sci. USA* 90, 2092-2096.
- Buxbaum, J. D., Koo, E. H., and Greengard, P. (1993). *Proc. Natl. Acad. Sci. USA* 90, 9185-9188.
- Cai, X., Golde, T., and Younkin, S. (1993). *Science* 259, 514-516.
- Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D. J. (1992). *Nature* 360, 672-674.
- Dovey, R., Suomensari-Chrysler, S., Lieberburg, I., Sinha, S., Keim, P. S. (1993). *Neuroreport* 4, 1039-1042.
- Esch, F., Keim, P., Beattie, E., Blacher, R., Culwell, A., Oltersdorf, T., McClure, D., and Ward, P. (1990). *Science* 248, 1122-1124.
- Estus, S., Golde, T., Kunishita, T., Blades, D., Lowery, D., Eisen, M., Uslak, M., Qu, X., Tabira, T., Greenberg, B., and Younkin, S. (1992). *Science* 255, 726-728.
- Golde, T., Estus, S., Younkin, L., Selkoe, D., and Younkin, S. (1992). *Science* 255, 728-730.
- Haass, C., Koo, E., Mellon, A., Hung, A. Y., and Selkoe, D. J. (1992a). *Nature* 357, 500-503.
- Haass, C., Schlossmacher, M., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B., Lieberburg, I., Koo, E., Schenk, D., Teplow, D., and Selkoe, D. J. (1992b). *Nature* 359, 322-325.
- Haass, C., Hung, A., Schlossmacher, M., Teplow, D., and Selkoe, D. (1993). *J. Biol. Chem.* 268, 3021-3024.
- Hardy, J. (1992). *Nature Genet.* 1, 233-234.
- Hung, A. Y., Haass, C., Nitsch, R. M., Qiao Qiu, W., Citron, M., Wurtman, R. J., Growdon, J. H., and Selkoe, D. J. (1993). *J. Biol. Chem.* 268, 22959-22962.
- Hung, A., and Selkoe, D. J. (1994). *EMBO J.*, in press.
- Jarrett, J., and Lansbury, P. (1993). *Cell* 73, 1055-1058.
- Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J., Masters, C., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., and Müller-Hill, B. (1987). *Nature* 325, 733-736.
- Mullan, M., Crawford, F., Houlden, H., Axelman, K., Lilius, L., Winblad, B., and Lannfelt, L. (1992). *Nature Genet.* 1, 345-347.
- Nitsch, R., Slack, B., Wurtman, R., and Growdon, J. (1992). *Science* 258, 304-307.
- Nordstedt, C., Caporaso, G., Thyberg, J., Gandy, S., and Greengard, P. (1993). *J. Biol. Chem.* 268, 606-612.
- Sambamurti, K., Shioi, J., Anderson J. P., Pappolla, M. A., and Robakis N. (1992). *J. Neurosci. Res.* 33, 319-329.
- Schellenberg, G., Bird, T., Wijsman, E., Orr, H., Anderson, L., Nemens, E., White, J., Bonnycastle, L., Weber, J., Alonso, E., Potter, H., Heston, L., and Martin, G. (1992). *Science* 258, 668-671.
- Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D. J., Lieberburg, I., and Schenk, D. (1992). *Nature* 359, 325-327.
- Seubert, P., Oltersdorf, T., Lee, M., Barbour, R., Blomquist, C., Davis, D., Bryant, K., Fritz, C., Galasko, D., Thal, L., Lieberburg, I., and Schenk, D. (1993). *Nature* 361, 260-262.
- Shoji, M., Golde, T., Ghiso, J., Cheung, T., Estus, S., Shaffer, L., Cai, X., McKay, D., Tintner, R., Frangione, B., and Younkin, S. (1992). *Science* 258, 126-129.
- Sisodia, S. S. (1992). *Proc. Natl. Acad. Sci. USA* 89, 6075-6079.
- Strittmatter, W. J., Saunders, A. M., Schmechel, D., Perciak-Vance, M., Enghild, J., Salvesen, G. S., and Roses, A. D. (1993). *Proc. Natl. Acad. Sci. USA* 90, 1977-1981.
- Weidemann, A., König, G., Bunke, D., Fischer, P., Salbaum, M., Masters, C., and Beyreuther, K. (1989). *Cell* 7, 115-126.
- Yankner, B., Duffy, L., and Kirschner, D. (1990). *Science* 250, 279-282.



# Generation of Amyloid $\beta$ Protein from Its Precursor Is Sequence Specific

Martin Citron, David B. Teplow,  
and Dennis J. Selkoe  
Department of Neurology  
Program in Neuroscience  
Harvard Medical School  
Center for Neurologic Diseases  
Brigham and Women's Hospital  
Boston, Massachusetts 02115

## Summary

Cerebral deposition of amyloid  $\beta$  protein ( $A\beta$ ) is an early and critical feature of Alzheimer's disease. Here we analyze the substrate requirements of proteases (" $\beta$ -secretases") that cleave the  $\beta$ -amyloid precursor protein ( $\beta$ APP) at the N-terminus of  $A\beta$  (Asp-597 of  $\beta$ APP<sub>695</sub>) in intact human cells. The cleavage requires a membrane-bound substrate but tolerates shifts in the distance of the hydrolyzed bond from the membrane. The major protease has a minimum recognition region of Val-594 to Ala-598; most substitutions in this sequence strongly decrease or eliminate  $A\beta$  production. Only the Swedish familial Alzheimer's disease mutation (K595N/M596L) strongly increases  $A\beta$  production. Moreover, in this mutant but not in the wild type, the entire cytoplasmic tail with its reinternalization signals can be deleted without affecting  $A\beta$  N-terminal cleavage, consistent with the concept that cleavage of this mutant occurs in a different cellular compartment than that of wild-type molecules. Our results have important implications for current intensive approaches to develop assays for and identify enzymes with  $\beta$ -secretase activity.

## Introduction

Alzheimer's disease is characterized by the progressive formation in the brain of insoluble amyloid plaques and vascular deposits consisting of the 4 kDa amyloid  $\beta$  peptide ( $A\beta$ ; Glenner and Wong, 1984; Masters et al., 1985).  $A\beta$  is proteolytically derived from a large integral membrane protein, the  $\beta$ -amyloid precursor protein ( $\beta$ APP). Four  $A\beta$ -containing isoforms of  $\beta$ APP, comprising 695, 714, 751, or 770 amino acids, have been described (Kang et al., 1987; Ponte et al., 1988; Tanzi et al., 1988; Kitaguchi et al., 1988; Golde et al., 1990). The two longer isoforms contain a serine protease inhibitory domain of the Kunitz type. After maturation within the endoplasmic reticulum and Golgi,  $\beta$ APP undergoes a constitutive " $\alpha$ -secretory" proteolytic cleavage to release the large soluble N-terminal ectodomain ( $APP_e$ ) and create a 10 kDa C-terminal fragment that remains membrane bound (Figure 1) (Weidemann et al., 1989; Esch et al., 1990; Oltschendorf et al., 1990; Sisodia et al., 1990). In this pathway,  $\beta$ APP is cleaved within the  $A\beta$  domain primarily between residues Lys-16 and Leu-17, precluding formation of intact  $A\beta$  (Esch et

al., 1990). Recently, it has been shown that alternative cleavage sites within the  $A\beta$  region can be used in different cells, suggesting that  $\alpha$ -secretase cleavage is likely to involve a diverse set of proteases (Zhong et al., 1994).

The enzyme(s) responsible for this  $\alpha$ -secretory cleavage has not yet been isolated, but indirect evidence suggests that the major form of  $\alpha$ -secretase is a membrane-bound enzyme that cleaves  $\beta$ APP on the plasma membrane (Sisodia, 1992). It has been suggested that the principal determinants of cleavage are an  $\alpha$ -helical conformation around the cleavage site and the distance of the hydrolyzed peptide bond from the membrane, not the primary structure in this region (Sisodia, 1992).  $A\beta$  must be generated by an alternative pathway that involves at least two proteolytic cuts, one at the N-terminus by an enzyme(s) designated  $\beta$ -secretase and one at the C-terminus by  $\gamma$ -secretase (Figure 1). Thus, a potential therapeutic strategy for decreasing  $A\beta$  deposition in Alzheimer's disease involves inhibition of specific enzymes performing one or both of these cuts.

$A\beta$  production and release are normal physiological events. The 4 kDa peptides precipitable by a variety of  $A\beta$ -specific antibodies are normally present in the media of  $\beta$ APP-expressing cultured cells and in human and rodent cerebrospinal fluid. Most of these 4 kDa peptides secreted from human kidney 293 cells, human M17 neuroblastoma cells, and human fetal mixed brain cultures indeed start at Asp-1 (Haass et al., 1992b; Shoji et al., 1992; Seubert et al., 1992; Busciglio et al., 1993) and contain approximately 40 amino acids. Interestingly, the amount of  $A\beta$  released into conditioned media is markedly increased by a double missense mutation (K595N/M596L; Figure 1) that occurs in a Swedish Alzheimer's disease family (Mullan et al., 1992), as seen both in transfected cell lines (Citron et al., 1992; Cai et al., 1993) and in primary skin fibroblasts from patients carrying the mutation (Citron et al., 1994). In addition to  $A\beta$ , a 3 kDa peptide ( $p3$ ) starting at Leu-17 is constitutively secreted. This peptide appears to be derived by  $\gamma$ -secretase cleavage of the 10 kDa C-terminal fragment of  $\beta$ APP following secretion of  $APP_e$  (Haass et al., 1993).  $p3$  has recently been detected in diffuse plaques in Alzheimer brain tissue (Gowing et al., 1994).

The precise intracellular site(s) of  $A\beta$  generation and the proteases involved in its production are poorly understood. However, recent radiosequencing studies have shown that  $\beta$ -secretase cleavage occurs at slightly different positions in different cell types. In 293 cells, approximately 80% of  $A\beta$  produced from wild-type  $\beta$ APP molecules starts at Asp-1, with the rest beginning at Val(-3) and Ile(-6) (Haass et al., 1992b); however, in primary skin fibroblasts, wild-type  $\beta$ APP is metabolized to the Asp-1 form of  $A\beta$  only (Citron et al., 1994), and in Madin-Darby canine kidney cells, primarily to a form starting at Arg-5 (Haass et al., 1994). These results suggest that different cell-specific proteases are capable of generating the N-terminus of  $A\beta$ .

In this study, the substrate requirements of the proteases ( $\beta$ -secretases) that liberate the N-terminus of  $A\beta$  in




Figure 1.  $\beta$ APP Structure and Processing

The schematic shows  $\beta$ APP<sub>695</sub> with the consensus N-linked glycosylation sites (CHO) and the restriction sites *AccI* (A), *XhoI* (X), and *BglII* (B). The part of the  $\beta$ APP molecule removed by the XB deletion is indicated. N, N-terminus; C, C-terminus; vertical bars, plasma membrane; black box, A $\beta$ . Solid horizontal lines represent the regions against which antibodies B5, C7, 1963, and R1280 were produced. The amino acid sequence of the A $\beta$  region of  $\beta$ APP is expanded. The position of the Swedish (sw) FAD mutation is indicated. The sites of the  $\alpha$ -,  $\beta$ -, and  $\gamma$ -secretase cleavages are marked by arrows. The exact site(s) of  $\gamma$ -secretase cleavage is unknown, but the majority of A $\beta$  molecules in Alzheimer brain tissue terminate at Val-40 or Ala-42 (Mori et al., 1992; Roher et al., 1993). The amino acids shown in bold type at the lower left were mutated in this study to the amino acids indicated in plain type;  $\Delta$  signifies a deletion.

293 cells and in SK-N-SH human neuroblastoma cells were analyzed. We show that these proteases depend on a membrane-bound  $\beta$ APP substrate but tolerate changes in the distance of the cleaved peptide bond from the membrane. We define a minimal recognition sequence, document that the major Asp-1 cleaving enzyme is highly sequence specific, and show that the  $\beta$ -secretase cleavage occurs prior to the  $\gamma$ -secretase cleavage. Further, we show that deletion of the entire cytoplasmic tail of  $\beta$ APP strongly influences the N-terminal cleavage pattern of wild-type but not of Swedish mutant  $\beta$ APP, consistent with the idea that the N-terminal cleavage of A $\beta$  in these two  $\beta$ APP forms occurs in two different intracellular compartments. Finally, we discuss the implications of our results for current intensive efforts to develop an assay for a  $\beta$ -secretase enzyme in human brain and to confirm its identity.

## Results

### A $\beta$ Production Does Not Require the N-Terminal Portion of $\beta$ APP

To define a minimal region of  $\beta$ APP that is obligatory for A $\beta$  N-terminal cleavage in intact human cells, two  $\beta$ APP<sub>695</sub> in-frame deletion constructs, in which the 859 bp fragment

from *XhoI* to *BglII* (Figure 1) is replaced by a 16 bp synthetic piece of DNA, were analyzed. In these constructs, amino acids 309–589, including the two N-glycosylation sites at 467–469 and 498–498 (Kang et al., 1987), are deleted. Introduction of this deletion into a plasmid carrying the wild-type  $\beta$ APP<sub>695</sub> cDNA created plasmid XB, while introduction into a plasmid carrying the  $\beta$ APP<sub>695</sub> sequence with the Swedish double missense mutation (Citron et al., 1992) (Figure 1) created plasmid XBsw. Upon transfection, both constructs resulted in the production of A $\beta$ , p3, and APP<sub>s</sub>, the latter being about 30 kDa smaller than the respective wild-type protein as a consequence of the deletion (Figure 2A). As with full-length  $\beta$ APP constructs, the Swedish mutation leads to a strong increase in the amount of A $\beta$  (Figure 2A). This experiment demonstrates that amino acids 309–589 are not specifically required for the  $\beta$ - and  $\gamma$ -secretory cleavages that generate A $\beta$  in intact cells and are not involved in the increase in A $\beta$  production observed in the Swedish mutation. Another internal deletion construct,  $\beta$ APP<sub>695</sub>/AX, in which amino acids 78–305, including the ectodomain phosphorylation site(s), were deleted (Hung and Selkoe, 1994) also still allowed A $\beta$  production (Hung and Selkoe, unpublished data), indicating that almost the entire  $\beta$ APP ectodomain was dispensable with respect to A $\beta$  production.

### Proteolytic Generation of the A $\beta$ N-Terminus Tolerates Changes of Distance to the Membrane

It has been postulated that  $\alpha$ -secretase cleaves  $\beta$ APP at a fixed distance from the membrane (Sisodia, 1992). To address whether the same is true for the A $\beta$  N-terminal cleavage, we engineered constructs with amino acid deletions between the A $\beta$  cleavage site and the stretch of A $\beta$  amino acids from 18 to 23, near the transmembrane domain that is required for  $\alpha$ -secretase cleavage (Sisodia, 1992). Two deletion constructs were analyzed: in  $\Delta$ 5–9 the amino acids RHDSG of A $\beta$  (601–605 of  $\beta$ APP<sub>695</sub>) are deleted, and in  $\Delta$ 9–12 the amino acids GYEV (605–608) are deleted. Both constructs still led to the production of A $\beta$  and p3 peptides, as well as an APP<sub>s</sub> molecule that is poorly detectable by the R1280 immunoprecipitating antibody, owing to the deletion (Figure 2B). This finding demonstrates that amino acids 5–12 of A $\beta$  are dispensable for protease recognition of the N-terminal cleavage site. Together with the results of the XB deletion (Figure 2A), it appears that the recognition sequence for  $\beta$ -secretase is limited to a maximum of 11 amino acids (positions 590–600) immediately surrounding the cleavage site. However, we cannot exclude the possibility that residues C-terminal to amino acid 608 might also assist in proper recognition. An analogous insertion construct in which the amino acids IGFEV were inserted after the 7th amino acid of A $\beta$  (position 603) led to a strong decrease in both A $\beta$  and p3, suggesting that this insertion had disrupted the overall structure of the molecule and thereby inhibited both  $\alpha$ - and  $\beta$ -secretase cleavages (data not shown). Relative to wild-type  $\beta$ APP, the A $\beta$  bands derived from both deletion constructs displayed decreased mobility (Figure 2B). This result suggests that the predominant Met–Asp cleavage site was maintained, independently of its membrane distance.




Figure 2. Antibody R1280 Immunoprecipitations of Conditioned Media from Metabolically Labeled Kidney 293 Cells Transiently Transfected with the Indicated Plasmids

(A) XhoI-BglII deletion constructs either without (XB) or with (XBsw) the Swedish double mutation. 0, untransfected; wt, transfected with wild-type  $\beta$ APP<sub>695</sub>. APP<sub>s</sub> marks the region of the gel in which conventional soluble forms of  $\beta$ APP migrate. APP<sub>s</sub><sup>\*</sup> marks the form of APP, that is shortened by ~30 kDa owing to the XB deletion. APP<sub>s</sub><sup>\*</sup> is stronger in XBsw than in XB, presumably because of higher transfection efficiency.

(B) A $\beta$  internal deletion constructs. In  $\Delta$ 5-9, A $\beta$  and p3 run as distinct but very closely spaced bands. Radiosequencing of the upper band confirms that it has A $\beta$  sequence (see Figure 3). Owing to the deletion of amino acids 9-12

and 5-9 of A $\beta$ , the C-terminus of APP, is much less well recognized by R1280. The ~200 kDa proteins detected in all immunoprecipitations and the ~70 kDa protein in (B) are nonspecific proteins that are unrelated to  $\beta$ APP (Haass et al., 1992b).

Radiosequencing of A $\beta$  from  $\Delta$ 5-9 and  $\Delta$ 9-12 transfectants demonstrated that this is indeed the case (Figures 3A and 3C). For A $\beta$  from both  $\Delta$ 5-9 and  $\Delta$ 9-12, major peaks of <sup>3</sup>H-phenylalanine were obtained at positions consistent with an A $\beta$  start at Asp-1 (peak of radioactivity at cycle 4) and the deletion of 5 or 4 amino acids, respectively, between Phe-4 and Phe-19/20 (double peaks of radioactivity at cycles 14/15 or 15/16, respectively). As expected, p3 is not influenced by the deletions, and therefore both constructs show a p3 radiosequencing pattern very similar to the one previously established for wild-type  $\beta$ APP (Haass et al., 1992b), with most of p3 starting at Leu-17 (Figures 3B and 3D). In summary, these data strongly suggest that the N-terminal cleavage generating A $\beta$  can tolerate a decrease of distance of the peptide bond from the membrane.

### Membrane Association of $\beta$ APP Is Required for $\beta$ -Secretase Cleavage

Next, we asked whether  $\beta$ APP must be membrane bound for A $\beta$  production to occur. To address this question, five constructs were designed (Figure 4A), transiently transfected into 293 cells, and checked for A $\beta$  production (Figure 4B). The wild-type  $\beta$ APP<sub>695</sub> construct shows the expected bands of APP<sub>s</sub>, A $\beta$ , and p3 (Figure 4B). The construct STOP51 contains a stop codon at position 648, after the 51st amino acid from the A $\beta$  start site (Figure 4A), thus including virtually the entire  $\beta$ APP transmembrane domain. This construct produces A $\beta$  and p3 comparably to the wild type (Figure 4B). However, products in the size range of APP<sub>s</sub> are markedly increased (see below). The construct STOP40 contains a stop codon at position 637, after the 40th amino acid from the A $\beta$  start (Figure 4A).





Figure 3. Radiosequencing of A $\beta$  and p3 Peptides Secreted by 293 Cells Transfected with the  $\Delta$ 5-9 and  $\Delta$ 9-12 Mutations

The <sup>3</sup>H-phenylalanine radioactivity obtained at each cycle of the Edman chemistry is graphed for the 4 kDa (A and C) and 3 kDa (B and D) bands. The sequences above (A) and (C) are correct for the  $\Delta$ 5-9 and  $\Delta$ 9-12 molecules, respectively, i.e., they lack the deleted amino acids. The radiolabeled phenylalanines are indicated by bold letters (F) in each peptide sequence.



**Figure 4. Membrane Insertion of βAPP Is Required to Generate Aβ**

(A) βAPP schematic showing the C-termini of STOP51 and STOP40 constructs and the NL substitution in the constructs STOP51sw and STOP40sw. The amino acids of the transmembrane domain are indicated in bold letters.

(B) Antibody R1280 immunoprecipitations of conditioned media from metabolically labeled 293 cells transiently transfected with the indicated plasmids.

(C) Antibody 1280 (Aβ<sub>1-40</sub>) and antibody 1963 (Aβ<sub>21-37</sub>) immunoprecipitations of conditioned media from metabolically labeled 293 cells transfected with the indicated plasmids.

(D) Antibody B5 (to the midregion epitope βAPP<sub>441-502</sub>) immunoprecipitations of total lysates of the cells used in (C). The principal endogenously expressed βAPP<sub>751</sub> precursor is indicated.

(E) Western blot of carbonate-extracted membrane preparations from kidney cells transfected with the indicated plasmids, using antibody B5. The two endogenous βAPP<sub>751</sub> bands are indicated. The βAPP<sub>695</sub> bands of the wild-type transfectant are marked (x). The lower molecular weight βAPP bands of the truncated STOP51sw construct are also marked (dots). This gel was run longer than (D) and therefore shows a clear separation of the N- and the N'4'O' glycosylated forms.

Thus, the resulting βAPP molecule terminates at the major cleavage position of γ-secretase (Figure 1) and would only need to undergo N-terminal cleavage to generate Aβ. This construct also produces very high amounts of material in the APP<sub>6</sub> size range, but secretes neither Aβ nor p3 (Figure 4B). Similar results were obtained with the constructs STOP51sw and STOP40sw, which contain the Swedish mutation in addition to the STOP51 or STOP40 deletion, respectively (Figure 4B).

The fact that the constructs STOP51 and STOP51sw secrete Aβ while STOP40 and STOP40sw do not strongly suggests that only membrane-bound βAPP can function as a substrate for the Aβ N-terminal protease. Both truncation constructs lack the βAPP cytoplasmic domain, thus excluding the possibility that loss of this region alone causes the complete lack of Aβ generation in STOP40 and STOP40sw. The only difference between the constructs is the length of the transmembrane region they contain: STOP40 and STOP40sw contain only 12 amino acids of the predicted 24 amino acid transmembrane domain (Kang et al., 1987), whereas STOP51 and STOP51sw contain 23. It is therefore likely that the βAPP of STOP51 and STOP51sw occurs in considerable part as a membrane-bound molecule, whereas βAPP of STOP40 and STOP40sw does not. To test this prediction, we prepared a set of five

dishes each from 293 cells that were either untransfected or transfected with βAPP<sub>695</sub>, STOP51sw, or STOP40sw constructs. Two dishes from each set were metabolically labeled. The conditioned media of these two dishes were pooled, and one-half was immunoprecipitated with R1280, which is directed against Aβ<sub>1-40</sub> (Figure 4C). This precipitation showed again that Aβ and p3 are secreted at levels clearly above the endogenous background by wild type- and STOP51sw-transfected cells but not by STOP40sw-transfected cells. The untransfected cells showed very little material in the APP<sub>6</sub> size range, the wild type-transfected cells show some APP<sub>6</sub>, and both the STOP51sw- and STOP40sw-transfected cells have strong bands of similar intensity in that size range (Figure 4C). The second half of the conditioned media was immunoprecipitated with 1963, an antibody to Aβ residues 21-37 beyond the α-secretase site that recognizes Aβ and p3 but cannot precipitate APP<sub>6</sub> ending at the α-secretase site (Figure 1). The Aβ and p3 precipitations from the various transfectants using antibody 1963 are similar to those obtained with R1280, with the p3 band being slightly more pronounced relative to the Aβ band (Figure 4C). However, a clear difference in immunoprecipitated material in the APP<sub>6</sub> range is obtained with 1963. No material above background is precipitated by 1963 from wild type-transfected

cells, indicating that they do not release significant amounts of uncleaved  $\beta$ APP from the membrane, as expected. In contrast, the STOP51sw-transfected cells clearly show some, and the STOP40sw-transfected cells show much more uncleaved  $\beta$ APP that has been released intact from the membrane, and can thus be precipitated from the medium with 1963. The STOP40sw construct releases much higher amounts of uncleaved precursor, but produces neither A $\beta$  nor p3; the latter, as an endproduct of the  $\alpha$ -secretory pathway (Haass et al., 1993), is predicted to arise solely from membrane-associated  $\beta$ APP (Sisodia, 1992).

If these differences in A $\beta$  (and p3) secretion from the STOP51sw and STOP40sw molecules are indeed due to their different levels of retention in cell membranes, one would expect to find full-length STOP51sw and STOP40sw molecules in comparable amounts in total cell lysates, but only STOP51sw molecules in isolated membrane preparations. Figure 4D shows total cell lysates from the two metabolically labeled dishes immunoprecipitated with the  $\beta$ APP midregion antibody, B5. All transfectants show the faint endogenous  $\beta$ APP<sub>751</sub> species. In addition, the wild-type transfectant has a major full-length band representing  $\beta$ APP<sub>695</sub> that migrates at a slightly lower molecular weight, as expected. The  $\beta$ APP from the STOP51 deletion construct is 48 amino acids shorter than the wild-type molecule, and that from the STOP40 deletion construct is 59 amino acids shorter; bands of accordingly lower molecular weight were indeed detected in these extracts. This result indicates that all constructs produce  $\beta$ APP molecules of the expected size in detectable amounts.

The remaining three dishes of each transfectant were used to prepare isolated carbonate-extracted membranes (see Experimental Procedures), which were then electrophoresed on SDS gels and immunoblotted with antibody B5 (Figure 4E). In all cases, the N'- and N'+O'-glycosylated forms of the endogenous  $\beta$ APP<sub>751</sub> were detected. In the  $\beta$ APP<sub>695</sub> wild-type transfectant, the N'+O'-glycosylated band of  $\beta$ APP (marked by the upper "x" in Figure 4E) comigrates with the N-glycosylated form of the endogenous  $\beta$ APP<sub>751</sub>. In addition, the N-glycosylated form of the transfected  $\beta$ APP<sub>695</sub> migrating at a slightly lower molecular weight (marked by the lower "x") is clearly detectable. Two bands of lower molecular weight representing the N'- and N'+O'-glycosylated forms of the truncated STOP51sw molecule (marked by dots in Figure 4E) were detected in the membranes of STOP51sw cells. In contrast, only extremely faint bands, besides the endogenous  $\beta$ APP<sub>751</sub>, background proteins, were detected in the STOP40sw deletion transfected cells. Together, Figures 4C–4E demonstrate that STOP40sw and STOP51sw are expressed and detectable in cell lysates. However, only STOP51sw is membrane inserted, and only STOP51sw undergoes the  $\beta$ -secretase cleavage necessary for A $\beta$  production.

#### Differential Substrate Requirements for $\beta$ -Secretase Cleavage of Wild-Type and Swedish $\beta$ APP<sub>695</sub>

The data presented in Figure 4 seem to suggest that the whole  $\beta$ APP C-terminus downstream of amino acid 648





Figure 5. Radiosequencing of Peptides Secreted by Cells Transfected with the STOP51 or STOP51sw Constructs

The <sup>3</sup>H-phenylalanine-derived radioactivity obtained at each cycle of the Edman chemistry is graphed.

(A) Production of the 4 kDa peptide with STOP51. The upper line at the top of the graph shows the sequence of the predominant species starting at Arg-5, and the lower line shows the sequence of A $\beta$  starting at Asp-1.

(B) Production of the 4 kDa peptide with STOP51sw. The sequence of the regular Asp-1 species is indicated.

(the endpoint of the STOP51 deletion) is dispensable for the production of A $\beta$ . However, it has been shown that a deletion of the C-terminus of wild-type  $\beta$ APP<sub>695</sub> downstream from amino acid 653 ( $\Delta$ C), including the reinternalization motif NPTY, decreases the amount of A $\beta$  produced in 293 cells (Haass et al., 1993), and that deletion of the reinternalization sequence YENPTY alone has the same effect in CHO cells (Koo and Squazzo, 1994). Furthermore, whereas the  $\Delta$ C mutation lowers the amount of A $\beta$  starting at Asp-1, radiosequencing demonstrates that it significantly increases the amounts of A $\beta$ -related peptides starting at Val(-3) (radioactive Phe at cycles 7, 22, and 23) and Arg-5 (radioactive Phe at cycles 15 and 16) relative to the amount of the Asp-1 A $\beta$  form in the same cells (Haass et al., 1993). Radiosequencing of A $\beta$  from STOP51-transfected 293 cells confirmed this observation (Figure 5A). Peptides starting at Arg-5 (radioactive Phe at cycles 15 and 16) become the predominant A $\beta$  species. Surprisingly, this cytoplasmic deletion effect is not observed in A $\beta$  from STOP51sw-transfected 293 cells (Figure 5B). Instead, a homogenous "Asp-1 only" N-terminal cleavage pattern is obtained. This pattern is typical for the effects



**Figure 6.** Immunoprecipitations of Conditioned Media and Cell Extracts from Metabolically Labeled Cells Transiently Transfected with the Indicated Plasmids

(A) R1280 immunoprecipitation of conditioned media from 293 transfectants.

(B) B5 immunoprecipitation of APP<sub>s</sub> from conditioned media of 293 transfectants.

(C) C7 immunoprecipitation of C-terminal βAPP fragments from cell extracts of 293 transfectants.

(D) R1280 immunoprecipitation of conditioned media from SK-N-SH neuroblastoma transfectants.

(E) B5 immunoprecipitation of APP<sub>s</sub> of conditioned media from SK-N-SH neuroblastoma cell transfectants. The APP<sub>s</sub> band resulting from transfection with these βAPP<sub>sw</sub> wild-type or mutant constructs is marked. The band immediately above it is the endogenous APP<sub>s</sub>.

(F) C7 immunoprecipitation of C-terminal βAPP fragments from cell extracts of SK-N-SH neuroblastoma cell transfectants.

(G) Radiosequencing of the 12 kDa band from extracts of SK-N-SH neuroblastoma cells transfected with Swedish mutant βAPP<sub>sw</sub> and precipitated with antibody C7. The <sup>3</sup>H-phenylalanine-derived radioactivity obtained at each cycle of the Edman chemistry is graphed. For the M596V mutation, the amounts of the 10 kDa fragment and p3 seem slightly increased in 293 cells (C) and strongly increased in SK-N-SH cells (F), probably owing to a compensatory increase in α-secretase cleavage when β-secretase cleavage is inhibited.

of the Swedish mutation in full-length βAPP molecules and different from the heterogeneous Aβ N-terminal cleavages of wild-type βAPP (Citron et al., 1994). Thus, whereas deletion of the entire cytoplasmic domain (or the YENPTY reinternalization signal alone) has a clear influence on β-secretase cleavage of wild-type βAPP, it has little or no effect on β-secretase cleavage of Swedish βAPP, consistent with the hypothesis that, for the latter molecule, β-secretase cleavage principally occurs before reinternalization of the precursor.

#### The N-Terminal Cleavage of Aβ Is Highly Sequence Specific

Previous experiments with transient and stable transfections of plasmids carrying the Swedish mutation suggest that amino acid substitutions at or near the N-terminal cleavage site can have profound effects on the amount of Aβ being produced in several types of cells (Citron et al., 1992; Cai et al., 1993). We therefore analyzed the effects of other amino acid substitutions in the region from Val(-3) (residue 594 of βAPP<sub>sw</sub>) to Ala-2 (residue 598) in

transient transfections. The substitution constructs are abbreviated with the letter of the original amino acid, its position number, and the letter of the substituted amino acid; amino acid deletions are indicated by Δ. As an example of this set of experiments, Figure 6 shows all the βAPP derivatives obtained from the mutants M596V and D597Δ in both 293 cells and SK-N-SH human neuroblastoma cells. Conditioned media of the transfected cells were precipitated with the APP<sub>s</sub>-reactive antibody B5, and all three constructs yielded APP<sub>s</sub> proteins of the same size and in comparable amounts, whether expressed in 293 cells (Figure 6B) or SK-N-SH neuroblastoma cells (Figure 6E). However, precipitation of the conditioned media with the Aβ-specific antibody R1280 revealed striking differences among the constructs: while all three transfectants produced p3, which started at Leu-17 (data not shown) and is not observed in untransfected SK-N-SH cells, M596V produced no Aβ (Figures 6A and 6D). Likewise, D597Δ did not produce the 4 kDa Aβ species, but instead a ~3.8 kDa peptide (Figures 6A and 6D) that started at Phe-4 (radiosequencing data not shown). These results were ob-




Figure 7. Antibody R1280 Immunoprecipitations of Conditioned Media from Metabolically Labeled 293 Cells Transiently Transfected with the Indicated Plasmids

(A) Mutations at V594 and K595. (B) Mutations at M596. (C) Mutations at D597. The amount of A $\beta$  in D597K is overestimated because a slightly smaller band is not clearly separable for the quantitation. (D) Mutations at A598. An untransfected control just expressing the endogenous  $\beta$ APP<sub>751</sub> is also shown (lane 0). For each panel, the ratio of A $\beta$  detected in conditioned medium to full-length  $\beta$ APP detected in the cell lysate of each transfectant was determined by phosphorimaging and normalized to the wild-type ratio, which was set at 1.0. The ratios are shown below each panel. The ratios in (C), especially for D597K, may be overestimated, since shortened A $\beta$  fragments overlap the 4 kDa range that was quantitated.

tained in both 293 cells (Figure 6A) and SK-N-SH cells (Figure 6D) after overnight labeling and were also seen after a 2 hr pulse labeling in the 293 cells (data not shown).

When cell extracts were precipitated with the C-terminal antibody C7, all transfected cells were found to overproduce membrane-bound, full-length  $\beta$ APP (data not shown) and a 10 kDa C-terminal fragment that remains membrane-bound after release of APP<sub>s</sub> into the medium (293 cells, Figure 6C; SK-N-SH cells, Figure 6F). An additional 12 kDa C-terminal fragment is observed in SK-N-SH neuroblastoma cells transfected with wild-type  $\beta$ APP<sub>695</sub> (Figure 6F). This band becomes much more pronounced in Swedish SK-N-SH transfectants, is barely detectable in the M596V transfectants, and is replaced by a shorter ~11.5 kDa band in the D597 $\Delta$  transfectant (Figure 6F). A C-terminal fragment of similar size has been previously observed to be increased in M17 human neuroblastoma cells transfected with  $\beta$ APP carrying the Swedish mutation and was thus hypothesized to be an immediate precursor of A $\beta$  that has not yet undergone  $\gamma$ -secretase cleavage (Cai et al., 1993). Indeed, both the amounts and the size of this fragment correlate with the amounts and the size of A $\beta$  in our various SK-N-SH transfectants (compare Figures 6D and 6F). Radiosequencing of the Swedish 12 kDa protein confirms that it indeed starts at Asp-1 (major peak of radioactive Phe in cycle 4; Figure 6G). It seems highly likely that the substitutions examined primarily influence the N-terminal cleavage of A $\beta$  and not other  $\beta$ APP proteolytic processing pathways, because we did not observe any substantial differences in cellular full-length  $\beta$ APP

(data not shown) or decreases in total APP<sub>s</sub> (Figures 6B and 6E).

We next set out to test an extensive panel of N-terminal substitutions for their effect on A $\beta$  production in 293 cells. For each substitution, the R1280 immunoprecipitates of A $\beta$  and p3 are shown in Figure 7. The relative ratios of A $\beta$  to full-length  $\beta$ APP, determined by phosphorimaging and set as 1.0 for the wild type in each panel, are indicated (Figure 7). All of the substitution mutants produced full-length  $\beta$ APP and APP<sub>s</sub> (data not shown). Likewise, p3 was secreted by all of the mutants analyzed, although in varying amounts. In contrast, A $\beta$  production was markedly affected by most substitutions. Changes at V594 strongly decreased A $\beta$  production, whereas no clear effect was observed for two substitutions for K595. Several substitutions at the p1 position M596 were analyzed. The previously described M596L substitution of the Swedish mutation (Citron et al., 1992) led to an increase in A $\beta$ . Of all the other substitutions, only the hydrophobic, bulky residues F and Y did not lead to a strong decrease in A $\beta$  (Figure 7B). The A $\beta$  4 kDa species was virtually eliminated by all the D597 substitutions. Only D597E still showed the original A $\beta$  band (Figure 7C). However, in all these D597 substitutions, intermediate bands of ~3.8 kDa appeared that were not observed from wild-type constructs (Figure 7C), as shown above for D597 $\Delta$  (Figure 6D). Substitutions of A598 also had a marked inhibitory effect on A $\beta$  production (Figure 7D). In summary, almost all of the single amino acid substitutions at and immediately around the N-terminal cleavage site markedly decreased A $\beta$  production.

## Discussion

In this work, we have used human 293 cells to establish the substrate requirements of proteases that cleave  $\beta$ APP at the N-terminus of A $\beta$ . We show that three  $\beta$ APP mutants producing strong, but distinct, effects on A $\beta$  production in this cellular system give essentially identical results in human SK-N-SH neuroblastoma cells. These data suggest that mutations around the Met-Asp cleavage site may lead to similar changes in A $\beta$  production in other neural and nonneural cell types. Our findings demonstrate that the region defined by residues 590–600 ( $\beta$ APP<sub>590-600</sub> numbering) is sufficient for recognition and efficient cleavage of the precursor by the A $\beta$  N-terminal protease(s). When the cleavage site is moved 5 amino acids closer to the membrane, there is no effect on cleavage, as demonstrated by N-terminal sequencing of the product. This result suggests that the protease(s), designated  $\beta$ -secretase(s), recognizes the primary structure around the cleavage site independently of its distance from the membrane, a property which is the opposite of that postulated for  $\alpha$ -secretase (Sisodia, 1992). The fact that  $\beta$ -secretases do not require a fixed distance to the membrane in order to cleave suggests that the proteases themselves are not membrane anchored. However, they can only act on membrane-bound  $\beta$ APP molecules in intact cells, because otherwise the STOP40 and STOP40sw forms of  $\beta$ APP would give rise to A $\beta$ , as do the STOP51 and STOP51sw constructs, which also lack the cytoplasmic domain but contain most of the transmembrane domain. The fact that only membrane-bound  $\beta$ APP is N-terminally cleaved *in vivo* implies that A $\beta$  is very unlikely to be produced extracellularly from larger secreted N- or C-terminal fragments of full-length  $\beta$ APP, at least not by the same proteases that produce A $\beta$  in intact cells.

Two lines of indirect evidence suggest that more than one protease can generate the N-terminus of A $\beta$ : first, the wild-type  $\beta$ APP molecule can be processed into A $\beta$ -related peptides starting at different positions in a cell type-dependent manner; second, the N-terminal sequence heterogeneity of A $\beta$  peptides produced in 293 cells suggests the action of more than one enzyme, particularly in view of our finding here that the Met-Asp cleaving enzyme is highly sequence specific. The results of substitutions at the p1 position, in which only the large hydrophobic residues Met, Leu, Phe, and Tyr allowed cleavage, are consistent with the primary cleavage at Asp-1 being produced by a chymotryptic-like proteinase. Based on our A $\beta$  sequencing data, this enzyme would be the only one capable of creating the A $\beta$  N-terminus in fibroblasts, would be the predominant enzyme in 293 cells, and would be virtually absent from the normal A $\beta$  production pathway in Madin-Darby canine kidney cells (in which A $\beta$  begins primarily at Arg-5).  $\beta$ APP substrates with mutations around the regular N-terminal cleavage site could then be recognized by other proteases with different specificities. This would explain the 3.8 kDa peptides that arise after virtually any substitution at D597. The situation is complicated further by the fact that not all enzymes capable of cleaving the N-terminus of A $\beta$  need necessarily be located in the same

subcellular compartment. It has recently been demonstrated that one site of A $\beta$  generation is within an early endosome following reinternalization of  $\beta$ APP from the cell surface (Koo and Squazzo, 1994). However,  $\beta$ APP molecules such as STOP51, in which the reinternalization signal is deleted, still produce A $\beta$ , albeit in reduced amounts and with increased levels of A $\beta$ -related peptides starting at positions other than Asp-1.

Most of the single amino acid substitutions we tested substantially decreased or eliminated A $\beta$  production. We believe this result is due to reduced cleavage at the A $\beta$  N-terminus rather than to decreased stability of the peptide or destruction of an epitope essential for the immunoprecipitation, because substitutions at V594 and M596 in front of the cleavage site would not influence antibody recognition or stability of a peptide starting at D597. Furthermore, the loss of the 4 kDa peptide in D597 $\Delta$  was also observed in a short-pulse experiment, arguing against A $\beta$  destabilization by substitution as a cause for its reduction in the D597 mutants. The fact that R1280 precipitates p3 shows that it does not recognize solely epitopes at the N-terminus of A $\beta$ . This makes it unlikely that single amino acid substitutions at the A $\beta$  N-terminus would completely block R1280 binding and thereby account for the disappearance of the 4 kDa band.

Our data underscore the previous conclusion that p3 arises from a different processing pathway than A $\beta$  (Haass et al., 1993). The fact that only the Swedish mutation, with its M596L substitution, clearly increases A $\beta$  production is consistent with the assumption that the Leu-Asp bond is a much better substrate than the wild-type Met-Asp bond for an Asp-1 cutting protease that cleaves  $\beta$ APP during its transport to the cell surface. This cleavage would happen prior to the reinternalization that appears to be necessary for the principal Asp-1 cleavage event in the wild-type substrate. Such a model would explain why the cleavage pattern of Swedish  $\beta$ APP is not affected by C-terminal truncations like STOP51sw that delete the internalization signals. Because none of the other mutants we examined besides M596L led to such a strong increase in A $\beta$  production, we speculate that any other polymorphisms around the cleavage site would also be phenotypically silent, making it unlikely that additional FAD mutations which cause increased A $\beta$  production will be mapped to the N-terminus of A $\beta$ .

The present investigation describes several properties of the  $\beta$ -secretase enzymes that produce A $\beta$  in living human cells and also allows two general conclusions about the C-terminal  $\gamma$ -secretase cleavage. First, the correlation of the amount of the 12 kDa C-terminal  $\beta$ APP fragment starting at Asp-1 with the amount of A $\beta$ , and the correlation of the amount of the respective 11.5 kDa fragment produced by D597 $\Delta$  with the amount of the shortened A $\beta$ -type peptide starting at Phe-4 in SK-N-SH cells, confirm the previous suggestion of Cai et al. (1993) that the 12 kDa fragment can serve as the immediate precursor of A $\beta$  and indicate that  $\beta$ -secretase cleavage occurs before  $\gamma$ -secretase cleavage. The 12 kDa molecule has not been observed, however, in transfected 293 cells (Figure 6C) (Citron et al., 1992) or in primary skin fibroblasts from patients



carrying the Swedish FAD mutation (Citron et al., 1994), suggesting that there are cell type differences in the rate at which the 12 kDa molecule undergoes  $\gamma$ -secretase cleavage. Second, because A $\beta$  is still produced from constructs like STOP51sw,  $\gamma$ -secretase does not require the cytoplasmic domain of  $\beta$ APP to recognize and cleave the C-terminus of A $\beta$ .

Finally, our description of the substrate specificity of the protease has important practical consequences. For example, our data suggest that  $\beta$ APP recombinant derivatives or synthetic peptides used to identify and characterize this protease must at least include Val-594 to Ala-598. Furthermore, one can now design control substrates with substitutions like M596V, which should not be cleaved well by the candidate protease. However, as we have shown here, only membrane-bound  $\beta$ APP undergoes N-terminal cleavage in vivo. If this need for membrane anchoring reflects a requirement of the protease rather than a requirement for substrate compartmentalization and targeting, then  $\beta$ APP derivatives and synthetic peptides that are not membrane bound should not be recognized by the protease for which they are designed. Therefore, the use of synthetic peptides or recombinant fragments in solution to screen for  $\beta$ -secretase might well lead to the isolation of irrelevant enzymes. These various considerations emphasize the importance of acquiring in vivo data in intact human cells when searching for physiologically relevant proteases.

#### Experimental Procedures

##### Transfection, Metabolic Labeling, Preparation of Total Cell Lysates, Immunoprecipitation, and Protein Radiosequencing

Details of these methods have been described previously (Haass et al., 1992b). Briefly, subconfluent 10 cm dishes of human embryonic kidney 293 cells or SK-N-SH human neuroblastoma cells were transiently transfected with 20  $\mu$ g of supercoiled plasmid DNA using Lipofectin (GIBCO/BRL) as described by the manufacturer. About 48 hr after transfection, cells were metabolically labeled with [ $^{35}$ S]methionine overnight. Immunoprecipitations were performed as described (Haass et al., 1992b). Immunoprecipitated APP, was separated on a 10% SDS-polyacrylamide gel, whereas precipitates of A $\beta$  and p3 from media and precipitates of cell extracts were separated on 10%–20% Tris-Tricine gels. Autofluorography was carried out as described (Haass et al., 1992b). Bands were quantitated by phosphorimaging. Radioactive sequencing of the 4 kDa (A $\beta$ ) and 3 kDa (p3) peptides was performed after R1280 immunoprecipitation of transiently transfected cells metabolically labeled with L-[2,3,4,5,6- $^3$ H]phenylalanine as described (Haass et al., 1992b).

##### Antibodies Used for Immunoprecipitation

The polyclonal antibody C7 (Podlisny et al., 1991) is directed against the last 20 amino acids of the cytoplasmic tail of  $\beta$ APP. This antibody immunoprecipitates N $^+$ - and N $^+$ -O $^+$ -glycosylated full-length  $\beta$ APP and the 10 kDa fragment. The affinity-purified polyclonal antibody B5 (Oltersdorf et al., 1990) was raised to a recombinantly expressed protein of  $\beta$ APP<sub>1-682</sub> and immunoprecipitates APP, and N $^+$ - and N $^+$ -O $^+$ -glycosylated full-length  $\beta$ APP. The polyclonal antibody R1280 (Tamaoka et al., 1992) was raised to synthetic A $\beta$ <sub>1-40</sub>. This antibody immunoprecipitates A $\beta$ , p3, and small, variable amounts of APP, from media of tissue culture cells (Haass et al., 1992b). The polyclonal antibody 1963 (Haass et al., 1992b) was raised to synthetic A $\beta$ <sub>21-37</sub>.

##### Plasmid Constructions

All constructs used in this paper are derivatives of pCMV695, a plasmid carrying  $\beta$ APP<sub>695</sub> cDNA under control of the CMV promoter (Selkoe

et al., 1988). Constructs containing single amino acid substitutions were designed by replacing the 26 bp BglII-EcoRI fragment of  $\beta$ APP<sub>695</sub> with annealed oligonucleotides in which codon 594, 595, 596, 597, or 598 was changed to encode the mutant amino acid: GTG was changed to TGG in V594W and deleted in V594 $\Delta$ ; AAG was changed to AAT in K595N and to GAG in K595E; ATG was deleted in M596 $\Delta$  and changed to CTG in M596L, to TAT in M596Y, to GTG in M596V, to GCC in M596A, to AAG in M596K, to GAG in M596E, to ATC in M596I, and to TTC in M596F; GAT was deleted in D597 $\Delta$  and changed to AAA in D597K, to GGA in D597G, to ATC in D597I, to AAC in D597N, and to GAA in D597E; GCA was deleted in A598 $\Delta$  and changed to GAG in A598E and to AAG in A598K. The plasmids XB and XBSw were engineered by deleting the XhoI-BglII fragment from pCMV695 and pCMV695 KM-NL (Citron et al., 1992), respectively, and replacing it with the annealed oligonucleotides TCGAGACACCTGGGGA and GATCTCCCCAGGTGTC. The plasmids  $\Delta$ 5–9,  $\Delta$ 9–12, Stop40, and Stop51 were generated by site-directed mutagenesis (Kunkel, 1985) of  $\beta$ APP<sub>695</sub> cDNA using the oligonucleotides: CCAATTTTGTGATGATGAACCTTC ATAGAATTCTGTAATCATGGTCAT, GAACACCAATTTTGTGATGTGAGTCATGTCGGAATTCGTAATC, GATCACTGTCGCTTAGACAACACCGCC, and CTGTTTCTTCTCTAGATAACCAAGGTGATGAC, respectively. The constructs STOP51sw and STOP40sw were engineered by replacing the wild-type EcoRI-SpeI fragment of the Swedish mutant construct  $\beta$ APP<sub>695</sub> KM-NL (Citron et al., 1992) with the EcoRI-SpeI fragment from STOP51 and STOP40, respectively. Except for XB, all mutations were verified by DNA sequencing.

##### Preparation of Isolated Membranes

A postnuclear supernatant was prepared as described previously (Haass et al., 1992a) and pelleted to remove cytoplasmic proteins by a high speed spin for 1 hr at 50,000 rpm (233,000 g) at 4°C in a Beckman 55Ti rotor. Isolated membranes were carbonate extracted as described (Fujiki et al., 1982). The homogenate was pelleted as described above. For each sample, 15  $\mu$ g of total protein were loaded on a 10% SDS-polyacrylamide gel. Transfer and immunoblotting were performed as described (Haass et al., 1992a).

##### Acknowledgments

This work was supported in part by NIH grants AG07911 (LEAD Award) and AG06173 to D. J. S.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC Section 1734 solely to indicate this fact.

Received July 18, 1994; revised December 20, 1994.


##### References

- Busciglio, J., Gabuzda, D. H., Matsudaira, P., and Yankner, B. A. (1993). Generation of  $\beta$ -amyloid in the secretory pathway in neuronal and nonneuronal cells. *Proc. Natl. Acad. Sci. USA* 90, 2092–2096.
- Cai, X.-D., Golde, T. E., and Younkin, S. G. (1993). Release of excess amyloid  $\beta$  protein from a mutant amyloid  $\beta$  protein precursor. *Science* 259, 514–518.
- Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D. J. (1992). Mutation of the  $\beta$ -amyloid precursor protein in familial Alzheimer's disease causes increased  $\beta$ -protein production. *Nature* 360, 672–674.
- Citron, M., Vigo-Pelfrey, C., Teplow, D. B., Miller, C., Schenk, D., Johnston, J., Winblad, B., Venizelos, N., Lannfelt, L., and Selkoe, D. J. (1994). Excessive production of amyloid  $\beta$ -protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. *Proc. Natl. Acad. Sci. USA* 91, 11993–11997.
- Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., and Ward, P. J. (1990). Cleavage of amyloid  $\beta$ -peptide during constitutive processing of its precursor. *Science* 248, 1122–1124.
- Fujiki, Y., Hubbard, A. L., Fowler, S., and Lazarow, P. B. (1982). Isolation of intracellular membranes by means of sodium carbonate treat-

- ment: application to endoplasmic reticulum. *J. Cell Biol.* 93, 97–102.
- Glennner, G. G., and Wong, C. W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem. Biophys. Res. Commun.* 120, 885–890.
- Golde, T. E., Estus, S., Usiak, M., Younkin, L. H., and Younkin, S. G. (1990). Expression of  $\beta$  amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR. *Neuron* 4, 253–267.
- Gowing, E., Roher, A. E., Woods, A. S., Cotter, R. J., Chaney, M., Little, S. P., and Ball, M. J. (1994). Chemical characterization of A $\beta$  17–42 peptide, a component of diffuse amyloid deposits of Alzheimer's disease. *J. Biol. Chem.* 269, 10987–10990.
- Haass, C., Koo, E. H., Mellon, A., Hung, A. Y., and Selkoe, D. J. (1992a). Targeting of cell-surface  $\beta$ -amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. *Nature* 357, 500–503.
- Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., and Selkoe, D. J. (1992b). Amyloid  $\beta$ -peptide is produced by cultured cells during normal metabolism. *Nature* 359, 322–325.
- Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B., and Selkoe, D. J. (1993).  $\beta$ -Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. *J. Biol. Chem.* 268, 3021–3024.
- Haass, C., Koo, E. H., Teplow, D. B., and Selkoe, D. J. (1994). Polarized secretion of  $\beta$ -amyloid precursor protein and amyloid  $\beta$ -peptide in MDCK cells. *Proc. Natl. Acad. Sci. USA* 91, 1564–1568.
- Hung, A. Y., and Selkoe, D. J. (1994). Selective ectodomain phosphorylation and regulated cleavage of the  $\beta$ -amyloid precursor protein. *EMBO J.* 13, 534–542.
- Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K., and Müller-Hill, B. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. *Nature* 325, 733–738.
- Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S., and Ito, H. (1988). Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity. *Nature* 331, 530–532.
- Koo, E. H., and Squazzo, S. L. (1994). Evidence that production and release of amyloid  $\beta$ -protein involves the endocytic pathway. *J. Biol. Chem.* 269, 17386–17389.
- Kunkel, T. M. (1985). Rapid and efficient site-specific mutagenesis without phenotypic selection. *Proc. Natl. Acad. Sci. USA* 82, 488–492.
- Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., and Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Natl. Acad. Sci. USA* 82, 4245–4249.
- Mori, H., Takio, K., Ogawara, M., and Selkoe, D. J. (1992). Mass spectrometry of purified amyloid  $\beta$  protein in Alzheimer's disease. *J. Biol. Chem.* 267, 17082–17086.
- Mullan, M., Crawford, F., Axelman, R., Houlden, H., Lilius, L., Winblad, B., and Lannfelt, L. (1992). A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of  $\beta$ -amyloid. *Nature Genet.* 1, 345–347.
- Oltersdorf, T., Ward, P. J., Henriksson, T., Beattie, E. C., Neve, R., Lieberberg, I., and Fritz, L. C. (1990). The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. *J. Biol. Chem.* 265, 4492–4497.
- Podlisy, M. B., Tolan, D., and Selkoe, D. J. (1991). Homology of the amyloid  $\beta$ -protein precursor in monkey and human supports a primate model for  $\beta$ -amyloidosis in Alzheimer's disease. *Am. J. Pathol.* 138, 1423–1435.
- Ponte, P., Gonzalez-DeWhitt, P., Schilling, J., Miller, J., Hsu, D., Greenberg, B., Davis, K., Wallace, W., Lieberburg, I., Fuller, F., and Cordell, B. (1988). A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. *Nature* 331, 525–527.
- Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., and Ball, M. J. (1993).  $\beta$ -Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer's disease. *Proc. Natl. Acad. Sci. USA* 90, 10836–10840.
- Selkoe, D. J., Podlisy, M. B., Joachim, C. L., Vickers, E. A., Lee, G., and Oltersdorf, T. (1988).  $\beta$ -Amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. *Proc. Natl. Acad. Sci. USA* 85, 7341–7345.
- Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., and Schenk, D. (1992). Isolation and quantitation of soluble Alzheimer's  $\beta$ -peptide from biological fluids. *Nature* 359, 325–327.
- Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., and Younkin, S. G. (1992). Production of the Alzheimer amyloid  $\beta$  protein by normal proteolytic processing. *Science* 258, 128–129.
- Sisodia, S. S. (1992).  $\beta$ -Amyloid precursor protein cleavage by a membrane-bound protease. *Proc. Natl. Acad. Sci. USA* 89, 6075–6079.
- Sisodia, S. S., Koo, E. H., Beyreuther, K., Unterbeck, A., and Price, D. L. (1990). Evidence that  $\beta$ -amyloid protein in Alzheimer's disease is not derived by normal processing. *Science* 248, 492–495.
- Tamaoka, A., Kalaria, R. N., Lieberburg, I., and Selkoe, D. J. (1992). Identification of a stable fragment of the Alzheimer amyloid precursor containing the  $\beta$ -protein in brain microvessels. *Proc. Natl. Acad. Sci. USA* 89, 1345–1349.
- Tanzi, R. E., McClatchey, A. I., Lamperti, E. D., Villa-Komaroff, L. L., Gusella, J. F., and Neve, R. L. (1988). Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease. *Nature* 331, 528–530.
- Weidemann, A., König, G., Bunke, D., Fischer, P., Salbaum, J. M., Masters, C. L., and Beyreuther, K. (1989). Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. *Cell* 57, 115–128.
- Zhong, Z., Higaki, J., Murakami, K., Wang, Y., Catalano, R., Quon, D., and Cordell, B. (1994). Secretion of  $\beta$ -amyloid precursor protein involves multiple cleavage sites. *J. Biol. Chem.* 269, 627–632.

# BIOCHEMISTRY

THIRD EDITION




LUBERT STRYER




STANFORD UNIVERSITY



W. H. FREEMAN AND COMPANY / NEW YORK


**Figure 2-8**  
Amino acids having aliphatic side chains.

Let us look at this repertoire of amino acids. The simplest one is *glycine*, which has just a hydrogen atom as its side chain (Figure 2-8). *Alanine* comes next, with a methyl group as its side chain. Larger hydrocarbon side chains (three and four carbons long) are found in *valine*, *leucine*, and *isoleucine*. These larger aliphatic side chains are *hydrophobic*—that is, they have an aversion to water and like to cluster. As will be discussed later, the three-dimensional structure of water-soluble proteins is stabilized by the coming together of hydrophobic side chains to avoid contact with water. The different sizes and shapes of these hydrocarbon side chains (Figure 2-9) enable them to pack together to form compact structures with few holes.

**Figure 2-9**  
Models of aliphatic amino acids**Figure 2-10**  
Proline differs from the other common amino acids in having a secondary amino group.

*Proline* also has an aliphatic side chain but it differs from other members of the set of twenty in that its side chain is bonded to both the nitrogen and  $\alpha$ -carbon atoms. The resulting cyclic structure (Figure 2-10) markedly influences protein architecture. Proline, often found in the bends of folded protein chains, is not averse to being exposed to water. Note that proline contains a secondary rather than a primary amino group, which makes it an *imino acid*.

Three amino acids with *aromatic side chains* are part of the fundamental repertoire (Figure 2-11). *Phenylalanine*, as its name indicates, contains a phenyl ring attached to a methylene ( $-\text{CH}_2-$ ) group. *Tryptophan* has an indole ring joined to a methylene group; this side chain contains a nitrogen atom in addition to carbon and hydrogen atoms.

**Figure 2-11**  
Phenylalanine, tyrosine, and tryptophan have aromatic side chains.




Figure 2-12  
Models of the aromatic amino acids.

Phenylalanine and tryptophan are highly hydrophobic. The aromatic ring of *tyrosine* contains a hydroxyl group, which makes tyrosine less hydrophobic than phenylalanine. Moreover, this hydroxyl group is reactive, in contrast with the rather inert side chains of all the other amino acids discussed thus far. The aromatic rings of phenylalanine, tryptophan, and tyrosine contain delocalized pi-electron clouds that enable them to interact with other pi-systems and to transfer electrons.

A sulfur atom is present in the side chains of two amino acids (Figure 2-13). *Cysteine* contains a sulfhydryl group ( $\text{—SH}$ ) and *methionine* contains a sulfur atom in a thioether linkage ( $\text{—S—CH}_3$ ). Both of these sulfur-containing side chains are hydrophobic. The sulfhydryl group of cysteine is highly reactive. As will be discussed shortly, cysteine plays a special role in shaping some proteins by forming disulfide links.




Figure 2-13  
Cysteine and methionine have sulfur-containing side chains.




Figure 2-14  
Models of cysteine and methionine.

Two amino acids, *serine* and *threonine*, contain aliphatic hydroxyl groups (Figure 2-15). Serine can be thought of as a hydroxylated version of alanine, and threonine as a hydroxylated version of valine. The hydroxyl groups on serine and threonine make them much more hydrophilic (water-loving) and reactive than alanine and valine. Threonine, like isoleucine, contains two centers of asymmetry. All other amino acids in the basic set of twenty, except for glycine, contain a single asymmetric center (the  $\alpha$ -carbon atom). Glycine is unique in being optically inactive.

We turn now to amino acids with very polar side chains, which render them highly hydrophilic. *Lysine* and *arginine* are positively charged at neutral pH. *Histidine* can be uncharged or positively charged, depending on its local environment. Indeed, histidine is often found in the active






Figure 2-15  
Serine and threonine have aliphatic hydroxyl side chains.



Arg

**Figure 2-17**


Model of arginine. The planar outer part of the side chain, consisting of three nitrogens bonded to a carbon atom, is called a guanidinium group.



Glu

**Figure 2-19**


Model of glutamate.

**Figure 2-16**

Lysine, arginine, and histidine have basic side chains.

sites of enzymes, where its imidazole ring can readily switch between these states to catalyze the making and breaking of bonds. These *basic amino acids* are depicted in Figure 2-16. The side chains of arginine and lysine are the longest ones in the set of twenty.

The repertoire of amino acids also contains two with *acidic side chains*, *aspartic acid* and *glutamic acid*. These amino acids are usually called *aspartate* and *glutamate* to emphasize that their side chains are nearly always negatively charged at physiological pH (Figure 2-18). Uncharged derivatives of glutamate and aspartate are *glutamine* and *asparagine*, which contain a terminal amide group in place of a carboxylate.

**Figure 2-18**

Acidic amino acids (aspartate and glutamate) and their amide derivatives (asparagine and glutamine).

Seven of the twenty amino acids have readily ionizable side chains. Equilibria and typical  $\text{pK}_a$  values for ionization of the side chains of arginine, lysine, histidine, aspartic and glutamic acids, cysteine, and tyrosine in proteins are given in Table 2-1. Two other groups in proteins, the terminal  $\alpha$ -amino group and the terminal  $\alpha$ -carboxyl group, can be ionized.

Amino acids are often designated by either a three-letter abbreviation or a one-letter symbol to facilitate concise communication (Table 2-2). The abbreviations for amino acids are the first three letters of their names, except for tryptophan (Trp), asparagine (Asn), glutamine (Gln), and isoleucine (Ile). The symbols for the small amino acids are the first letters of their names (e.g., G for glycine and L for leucine); the other symbols have been agreed upon by convention. These abbreviations and symbols are an integral part of the vocabulary of biochemists.

**Table 2-1**  
pK values of ionizable groups in proteins

Group	Acid $\rightleftharpoons$ base + $H^+$	Typical pK*
Terminal carboxyl	$-COOH \rightleftharpoons -COO^- + H^+$	3.1
Aspartic and glutamic acid	$-COOH \rightleftharpoons -COO^- + H^+$	4.4
Histidine	$  \begin{array}{c}  -CH_2 \\    \\  \text{+HN} \quad \text{NH} \\  \diagup \quad \diagdown \\  \text{C} \\  \diagdown \quad \diagup \\  \text{NH} \quad \text{NH}  \end{array}  \rightleftharpoons  \begin{array}{c}  -CH_2 \\    \\  \text{N} \quad \text{NH} \\  \diagup \quad \diagdown \\  \text{C} \\  \diagdown \quad \diagup \\  \text{NH} \quad \text{NH}  \end{array}  + H^+  $	6.5
Terminal amino	$-NH_3^+ \rightleftharpoons -NH_2 + H^+$	8.0
Cysteine	$-SH \rightleftharpoons -S^- + H^+$	8.5
Tyrosine	$  \begin{array}{c}  \text{---} \text{C}_6\text{H}_4 \text{---} \text{OH} \\  \rightleftharpoons \\  \text{---} \text{C}_6\text{H}_4 \text{---} \text{O}^-  \end{array}  + H^+  $	10.0
Lysine	$-NH_3^+ \rightleftharpoons -NH_2 + H^+$	10.0
Arginine	$  \begin{array}{c}  \text{H} \quad \text{NH}_2^+ \\  \diagdown \quad \diagup \\  \text{N} \text{---} \text{C} \\  \diagup \quad \diagdown \\  \text{NH}_2  \end{array}  \rightleftharpoons  \begin{array}{c}  \text{H} \quad \text{NH} \\  \diagdown \quad \diagup \\  \text{N} \text{---} \text{C} \\  \diagup \quad \diagdown \\  \text{NH}_2  \end{array}  + H^+  $	12.0

\*pK values depend on temperature, ionic strength, and the microenvironment of the ionizable group.

**Table 2-2**  
Abbreviations for amino acids

Amino acid	Three-letter abbreviation	One-letter symbol
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Asparagine or aspartic acid	Asx	B
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glutamine or glutamic acid	Glx	Z
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gurney et al. ) For: Alzheimer's Disease Secretase, APP  
Examiner: S. Turner ) Substrates Therefor, and Uses Thereof  
Group: 1647 )

DECLARATION OF MICHAEL BIENKOWSKI, Ph.D.  
PURSUANT TO 37 C.F.R. § 1.132

Commissioner for Patents  
Washington, DC 20231

Sir:

I, Michael Jerome Bienkowski, Ph.D., hereby declare as follows:

**I. Introduction**

1. I am a co-inventor of Asp2 subject matter claimed in various patent applications filed by Pharmacia & Upjohn. I make this declaration to provide information to the Patent Office that may be relevant to patent issues relating to enzymatically active, "transmembrane-deleted" forms ( $\Delta$ TM) of the Asp2 protein and polynucleotides which encode such protein. When I refer to "I" or "we" in this declaration, I mean me and/or my co-inventors and/or people working under our direction at Pharmacia & Upjohn.

2. The term "Asp2" is the name that we gave to aspartyl protease polynucleotides and polypeptides that we isolated and described in the patent applications. At least two human and one murine form of Asp2 are taught in the patent applications. Through experiments described in the patent applications we demonstrated that Asp2 exhibits proteolytic activity towards amyloid precursor protein (APP) involved in processing APP into amyloid beta ( $A\beta$ ), a peptide implicated in Alzheimer's Disease pathology.

**II. Cloning of Asp2 and Identifying the Asp2 transmembrane domain**

3. My co-inventors and I performed and/or directed experiments which resulted in the identification and cloning of human Asp2 cDNAs. Our earliest experiments did not immediately yield full-length Asp2 cDNAs. We first obtained and sequenced two



partial clones denoted as clone 4386993 (hereinafter '438) and clone 2696295 (hereinafter '269). As explained in our patent applications, Clone '438 contains additional codons sequence at its 5' end relative to clone '269, but Clone '269 contains 25 additional codons (75 basepairs) as an internal insertion relative to Clone '438. (These 25 codons represent the difference between the long and short forms of full length human Asp2 in Figures 2 and 3 of the patent applications.)

4. After we sequenced the '438 and '269 clones we aligned the sequences with sequences of other aspartyl proteases as part of our analysis of them. From these alignments and other analysis we deduced that these sequences were incomplete cDNA sequences that were truncated at the 5' end (the amino-terminus of the encoded polypeptide). Computer-aided analysis of the predicted amino acid sequences indicated that the predicted amino acid sequence encoded by both '438 and '269 contained the DTG/DSG sequences indicative of the aspartyl protease active site, and were complete to the carboxyl-terminus of the encoded polypeptide.

5. By analyzing the partial Asp2 sequence from the '438 and '269 clones described in paragraph 3, we deduced that Asp2 contained a transmembrane domain. Our U.S. Provisional Application No. 60/101,594, filed September 24, 1998, describes the analysis as follows:

Routine computer-aided analysis of the predicted amino acid sequence of Hu-Asp2a and Hu-Asp2(b) for secondary structure motifs resulted in detection of a predicted transmembrane domain in each polypeptide, which corresponds to Hu-Asp2(a) amino acid residues 367-392 of SEQ ID NO: 4, and of the sequence given in Figure 2, and to Hu-Asp 2(b) amino acid residues 392-417 of SEQ ID NO: 6, and of the sequence given in Figure 3.

(See U.S. Provisional Application No.60/101,594 at p. 20.)

As I explain in greater detail below, the stated location of the transmembrane sequences (367-392) and (392-417), through an inadvertent error, do not correspond to the transmembrane regions of the full length human Asp2(a) and Asp2(b) proteins shown in the Figures, and standing alone, these numbers would not serve as a basis for identifying the transmembrane region of the human Asp2 sequences. However, our routine computer-aided

analysis did, in fact, permit us to identify the Asp2 transmembrane region, and a molecular biologist of ordinary ability who read the application and (through the guidance of the application) performed his/her own routine computer-aided analysis would have identified the correct location of the transmembrane region in our Asp2 sequences.

6. Through our continued research we ultimately cloned additional 5' (amino terminal) cDNA sequence for the two human Asp2 enzyme isoforms. As reported in our patent applications, the longer full length human Asp2 cDNA has 501 codons.<sup>1</sup> (Figure 3 of the patent applications.) As correctly reported in our 1999 patent applications, the transmembrane domain of this Asp2 clone spans approximately residues 455 to 477 of the full length Asp2 sequence.

7. Looking back, I believe that the inadvertent error in the 60/155,493 application occurred because our research team had performed some of the routine computer-aided analysis on a partial Asp2 sequence from the '438 clone, and reported the data from this analysis for the full length Asp2 clone in the patent application. The analysis of the partial sequence from the '438 clone indicated that the transmembrane domain corresponded approximately to residues 367-392 of the partial sequence. (See Exhibit A hereto, which is a computer-assisted analysis of Asp2 (clone '438) sequence for possible transmembrane domains, performed prior to September 24, 1998, which indicates a likely TM region at about 367-392 of the sequenced analyzed.) I believe that the numbers from this analysis of the '438 partial sequence were reported in the 60/155,493 application for the full length short form (Figure 2) of human Asp2.<sup>2</sup> Since the patent application reported the full length Asp2 sequences, the numbers that were generated using the '438 clone partial sequence should have been adjusted upward for the patent application, to account for the extra codons at the beginning of the full length clone that were missing from the '438 clone partial sequence

---

<sup>1</sup> An Asp2 splice variant described in our patent application has 476 codons by virtue of the internal deletion of 25 codons described above in paragraph 3. (Figure 2 of the patent applications.) As reported correctly our 1999 patent applications, the transmembrane domain of this sequence corresponds approximately to residues 430-452.

<sup>2</sup> An upward adjustment of these numbers (by 25 codons) was used for the long form of Asp2 (Figure 3).

analyzed. But, through inadvertent error when preparing the patent application, this adjustment was not made.

8. In my opinion, this error would have been apparent to an average scientist in the field who evaluated the application, as would the proper correction of the error. In particular, it is commonly understood by molecular biologists that a transmembrane domain is characterized by a stretch of about 20-25 mostly hydrophobic amino acids. When a biologist read the application's teaching that Asp2 had a transmembrane domain near the carboxy-terminus and then examined the sequence to look for that transmembrane domain, it would have been readily apparent that the transmembrane domain was at about residues 455-477 (of Figure 3), and not residues 392-417.

**III. Invention-related activity for Asp2 ATM polynucleotides and polypeptides.**

9. The attorneys for Pharmacia & Upjohn have asked me to authenticate and discuss certain documents relating to our Asp2 invention.

10. Exhibit B hereto comprises excerpts from our U.S. Provisional Application No. 60/101,594. These excerpts establish that, on or before our filing date of September 24, 1998, we had possession of two human Asp2 cDNA and deduced Asp2 amino acid sequences (Figures 2 and 3) and determined various Asp2 structural features, including the presence of a transmembrane domain. It shows that we contemplated vectors and host cells for recombinant production of Asp2 polypeptides and enzymatically active polypeptide fragments (see, e.g., pp. 4, 5, and 9), and that we contemplated Asp2 antibodies (see, e.g., pp. 4, 12.) It shows that we contemplated expression of Asp2 in a variety of expression systems, including prokaryotes such as *E. coli* (pp. 9 and 10), yeasts such as *S. cerevisiae* (pp. 9, 11), and higher eukaryotes such as insect cell systems and mammalian systems, including COS cells, CHO cells, and human cells (see, e.g., pp. 9, 11-12).

11. Exhibit C hereto is a copy of a page from a Pharmacia & Upjohn interoffice memo from prior to our September 24, 1998, filing date, containing a report on the Human Asp2 project. Among other things, this excerpt shows that, prior to September 24,

1998, we had engineered the Asp2 open reading frame (ORF) from the '438 and '269 clones to remove the transmembrane domains, and that we had inserted these  $\Delta$ TM constructs into an *E. coli* expression vector pQE30.

12. Exhibit D hereto are copies of pages from a Pharmacia & Upjohn laboratory notebook. These pages establish that, prior to December 31, 1998, we had made a human Asp 2  $\Delta$ TM construct containing the DNA sequence coding for human Asp2 amino acids 1-454 (long form shown in Figure 3 of patent applications) in a baculovirus expression vector pVL 1353 (hu Asp 2  $\Delta$ TM pVL 1353) for expression in SF9 insect cells. This construct was sent for sequencing and the sequence was confirmed. Exhibit E hereto are copies of pages from a Pharmacia & Upjohn laboratory notebook. These pages establish that after December 31, 1998, we had made similar constructs with 6-histidine tags to facilitate protein purification.

13. Exhibit F hereto are copies of pages from Pharmacia & Upjohn laboratory notebooks which show that, prior to March 26, 1999, we had expressed human Asp2  $\Delta$ TM protein (without  $\beta$  secretase enzyme activity) in *E. Coli* to make antibodies for use in testing of recombinant expression of human Asp2  $\Delta$ TM in other cell types.

14. Exhibit G hereto are copies of pages from a Pharmacia & Upjohn laboratory notebook which show that, prior to March 26, 1999, we had made, isolated, and scaled-up preparations of viral plaques for production of a human Asp2  $\Delta$ TM construct in SF9 insect cells.

15. Exhibit H hereto contains copies of pages from a Pharmacia & Upjohn laboratory notebook which show that, after December 31, 1998, and prior to June 15, 1999, and prior to September 23, 1999, the scale-up results from SF9 were analyzed. Exhibit I are copies of a Pharmacia and Upjohn laboratory notebook showing a gel depicting the results of such analysis. A clean band of human Asp2  $\Delta$ TM expressed protein was identified by Western blot as shown in the notebook. This band is believed to contain active human  $\Delta$ TM Asp2 1-454 protein expressed in the SF9 system.

16. Exhibit J are copies of pages from a Pharmacia & Upjohn laboratory notebook showing that, after March 26, 1999, but prior to September 23, 1999, we excised the 1-454 Asp2  $\Delta$ TM coding segment from the pVL 1393 vector described above, inserted it into PIZ vector, and expressed this Asp2  $\Delta$ TM construct in High Five Cells. We tested this recombinant human Asp2  $\Delta$ TM protein and showed that it retained human Asp2 enzymatic activity. This work is also generally described in the patent applications that we filed on September 23, 1999, including PCT/US99/20881, U.S. Provisional Application No. 60/155,495, and U.S. Application Serial No. 09/404,133.

17. As shown in part by the representative documents referred to in the preceding paragraphs, during the period prior to September 24, 1998, until September 23, 1999, we were engaged in substantially continuous activity to make enzymatically active human Asp2 protein lacking a transmembrane domain, using materials and methods that we had contemplated in our September 24, 1998, patent application and/or had produced by that September 24, 1998 filing date.

#### IV. Certification

18. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: November 30, 2001

  
Michael Jerome Binkowski, Ph.D.

# Exhibit A

Figure 3 Alignment of Prosite Aspartyl protease consensus sequence with active site motifs in Hu\_Asp-2


[LIVMFGAC] - [LIVMTADN] - [LIVFSA] - D - [ST] - G - [STAV] - [STAPDENQ] - X -  
[LIVMFSTNC] - X - [LIVMFGTA]

N-Terminal motif: ILVDTGSSNFAV

[LIVMFGAC] - [LIVMTADN] - [LIVFSA] - D - [ST] - G - [STAV] - [STAPDENQ] - X -  
[LIVMFSTNC] - X - [LIVMFGTA]

C-Terminal motif: SIVDSGTTNLRL

Figure 4



# Exhibit B



In a preferred embodiment, the nucleic acid molecules comprise a polynucleotide having a nucleotide sequence selected from the group consisting of residues 21-1290 of SEQ ID NO:1, encoding Hu-Asp1, residues 84-1325 of SEQ ID NO:3, encoding Hu-Asp2(a), and residues 84-1400 of SEQ ID NO:5, encoding Hu-Asp2(b). In another aspect, the invention provides an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide encoding Hu-Asp1, Hu-Asp2(a), Hu-Asp2(b), or fragments thereof. European patent application EP 0 848 062 discloses a polypeptide referred to as "Asp 1," that bears substantial homology to Hu-Asp1, while international application WO 98/22597 discloses a polypeptide referred to as "Asp 2," that bears substantial homology to Hu-Asp2a.

The present invention also provides vectors comprising the isolated nucleic acid molecules of the invention, host cells into which such vectors have been introduced, and recombinant methods of obtaining a Hu-Asp1, Hu-Asp2(a), or Hu-Asp2(b) polypeptide comprising culturing the above-described host cell and isolating the relevant polypeptide.

In another aspect, the invention provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof. In a preferred embodiment, the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides have the amino acid sequence given in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, respectively. Isolated antibodies, both polyclonal and monoclonal, that bind specifically to any of the Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides of the invention are also provided.

The invention also provides a method for the identification of an agent that modulates the activity of any of Hu-Asp-1, Hu-Asp2(a), and Hu-Asp2(b).

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Figure 1 shows the nucleotide (SEQ ID NO:1) and predicted amino acid sequence (SEQ ID NO:2) of human Asp1.

Figure 2: Figure 2 shows the nucleotide (SEQ ID NO:3) and predicted amino acid sequence (SEQ ID NO:4) of human Asp2(a).

Figure 3: Figure 3 shows the nucleotide (SEQ ID NO:5) and predicted amino acid sequence (SEQ ID NO:6) of human Asp2(b). The predicted transmembrane domain of Hu-Asp2(b) is enclosed in brackets.

Figure 4: Figure 4 shows the sequence (SEQ ID NO: ) of APP695 C-terminus after addition of the di-Lys motif using "patch" PCR.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention describes a method to scan gene data bases for the simple active site motif characteristic of aspartyl proteases. Eukaryotic aspartyl proteases such as pepsin and renin possess a two domain structure which folds to bring two aspartyl residues into proximity within the active site. These are embedded in the short tripeptide motif DTG, or more rarely, DSG. Most aspartyl proteases occur as proenzyme whose N-terminus must be cleaved for activation. The DTG or DSG active site motif appears at about residue 65-70 in the proenzyme (prorenin, pepsinogen), but at about residue 25-30 in the active enzyme after cleavage of the N-terminal prodomain. The limited length of the active site motif makes it difficult to search collections of short, expressed sequence tags (EST) for novel aspartyl proteases. EST sequences typically average 250 nucleotides or less, and so would encode 80-90 amino acid residues or less. That would be too short a sequence to span the two active site motifs. The preferred method is to scan data bases of hypothetical or assembled protein coding sequences. The present invention describes a computer method to identify candidate aspartyl proteases in protein sequence data bases. The method was used to identify seven candidate aspartyl protease sequences in the *Caenorhabditis elegans* genome. These sequences were then used to identify by homology search Hu-Asp1 and two alternative splice variants of Hu-Asp2, designated herein as Hu-Asp2(a) and Hu-Asp2(b).

In another embodiment, the invention provides isolated nucleic acid molecules comprising a polynucleotide encoding a polypeptide selected from the group consisting of human aspartyl protease 1 (Hu-Asp1) and two alternative splice variants of human aspartyl protease 2 (Hu-Asp2), designated herein as Hu-Asp2(a) and Hu-Asp2(b). As used herein, all references to "Hu-Asp2" should be understood to refer to both Hu-Asp2(a) and Hu-Asp2(b). Hu-Asp1 is expressed most abundantly in pancreas and prostate tissues, while Hu-Asp2(a) and Hu-Asp2(b) are expressed most abundantly in pancreas and brain tissues, with low levels of expression observed in all other tissues examined except thymus and PBLs. The invention also provides isolated Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b) polypeptides, as well as fragments thereof which exhibit aspartyl protease activity.

The predicted amino acid sequences of Hu-Asp1, Hu-Asp2(a) and Hu-Asp2(b) share significant homology with previously identified mammalian aspartyl proteases such as pepsinogen A, pepsinogen B, cathepsin D, cathepsin E, and renin. P.B.Szeacs, *Scand. J. Clin. Lab. Invest.* 52:(Suppl. 210 5-22 (1992)). These enzymes are characterized by the presence of a duplicated DTG/DSG sequence motif. The Hu-Asp1 and Hu-Asp2

may be similar to or significantly different from a native Hu-Asp polypeptide in molecular weight and glycosylation pattern. Expression of Hu-Asp in bacterial expression systems will provide non-glycosylated Hu-Asp.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. Hu-Asp polypeptides may be recovered and purified from recombinant cell cultures by well-known methods, including ammonium sulfate or ethanol precipitation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. In a preferred embodiment, high performance liquid chromatography (HPLC) is employed for purification.

The present invention also relates to vectors comprising the polynucleotide molecules of the invention, as well as host cell transformed with such vectors. Any of the polynucleotide molecules of the invention may be joined to a vector, which generally includes a selectable marker and an origin of replication, for propagation in a host. Because the invention also provides Hu-Asp polypeptides expressed from the polynucleotide molecules described above, vectors for the expression of Hu-Asp are preferred. The vectors include DNA encoding any of the Hu-Asp polypeptides described above or below, operably linked to suitable transcriptional or translational regulatory sequences, such as those derived from a mammalian, microbial, viral, or insect gene. Examples of regulatory sequences include transcriptional promoters, operators, or enhancers, mRNA ribosomal binding sites, and appropriate sequences which control transcription and translation. Nucleotide sequences are operably linked when the regulatory sequence functionally relates to the DNA encoding Hu-Asp. Thus, a promoter nucleotide sequence is operably linked to a Hu-Asp DNA sequence if the promoter nucleotide sequence directs the transcription of the Hu-Asp sequence.

Selection of suitable vectors to be used for the cloning of polynucleotide molecules encoding Hu-Asp, or for the expression of Hu-Asp polypeptides, will of course depend upon the host cell in which the vector will be transformed, and, where applicable, the host cell from which the Hu-Asp polypeptide is to be expressed. Suitable host cells for expression of Hu-Asp polypeptides include prokaryotes, yeast, and higher eukaryotic cells, each of which is discussed below.

The Hu-Asp polypeptides to be expressed in such host cells may also be fusion proteins which include regions from heterologous proteins. Such regions may be included to

allow, *e.g.*, secretion, improved stability, or facilitated purification of the polypeptide. For example, a sequence encoding an appropriate signal peptide can be incorporated into expression vectors. A DNA sequence for a signal peptide (secretory leader) may be fused in-frame to the Hu-Asp sequence so that Hu-Asp is translated as a fusion protein comprising the signal peptide. A signal peptide that is functional in the intended host cell promotes extracellular secretion of the Hu-Asp polypeptide. Preferably, the signal sequence will be cleaved from the Hu-Asp polypeptide upon secretion of Hu-Asp from the cell. Non-limiting examples of signal sequences that can be used in practicing the invention include the yeast I-factor and the honeybee melatin leader in sf9 insect cells.

In a preferred embodiment, the Hu-Asp polypeptide will be a fusion protein which includes a heterologous region used to facilitate purification of the polypeptide. Many of the available peptides used for such a function allow selective binding of the fusion protein to a binding partner. For example, the Hu-Asp polypeptide may be modified to comprise a peptide to form a fusion protein which specifically binds to a binding partner, or peptide tag. Non-limiting examples of such peptide tags include the 6-His tag, thioredoxin tag, hemagglutinin tag, GST tag, and OmpA signal sequence tag. As will be understood by one of skill in the art, the binding partner which recognizes and binds to the peptide may be any molecule or compound including metal ions (*e.g.*, metal affinity columns), antibodies, or fragments thereof, and any protein or peptide which binds the peptide, such as the FLAG tag.

Suitable host cells for expression of Hu-Asp polypeptides include prokaryotes, yeast, and higher eukaryotic cells. Suitable prokaryotic hosts to be used for the expression of Hu-Asp include bacteria of the genera *Escherichia*, *Bacillus*, and *Salmonella*, as well as members of the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*. For expression in, *e.g.*, *E. coli*, a Hu-Asp polypeptide may include an N-terminal methionine residue to facilitate expression of the recombinant polypeptide in a prokaryotic host. The N-terminal Met may optionally then be cleaved from the expressed Hu-Asp polypeptide.

Expression vectors for use in prokaryotic hosts generally comprise one or more phenotypic selectable marker genes. Such genes generally encode, *e.g.*, a protein that confers antibiotic resistance or that supplies an auxotrophic requirement. A wide variety of such vectors are readily available from commercial sources. Examples include pSPORT vectors, pGEM vectors (Promega), pPROEX vectors (LTI, Bethesda, MD), Bluescript vectors (Stratagene), and pQE vectors (Qiagen).

Hu-Asp may also be expressed in yeast host cells from genera including *Saccharomyces*, *Pichia*, and *Kluyveromyces*. Preferred yeast hosts are *S. cerevisiae* and *P. pastoris*. Yeast vectors will often contain an origin of replication sequence from a 2T yeast plasmid, an autonomously replicating sequence (ARS), a promoter region, sequences for polyadenylation, sequences for transcription termination, and a selectable marker gene. Vectors replicable in both yeast and *E. coli* (termed shuttle vectors) may also be used. In addition to the above-mentioned features of yeast vectors, a shuttle vector will also include sequences for replication and selection in *E. coli*. Direct secretion of Hu-Asp polypeptides expressed in yeast hosts may be accomplished by the inclusion of nucleotide sequence encoding the yeast I-factor leader sequence at the 5' end of the Hu-Asp-encoding nucleotide sequence.

Insect host cell culture systems may also be used for the expression of Hu-Asp polypeptides. In a preferred embodiment, the Hu-Asp polypeptides of the invention are expressed using a baculovirus expression system (see Example 3). Further information regarding the use of baculovirus systems for the expression of heterologous proteins in insect cells are reviewed by Luckow and Summers, *Bio/Technology* 6:47 (1988).

In another preferred embodiment, the Hu-Asp polypeptide is expressed in mammalian host cells. Non-limiting examples of suitable mammalian cell lines include the COS-7 line of monkey kidney cells (Ghuzman *et al.*, *Cell* 23:175 (1981)) and Chinese hamster ovary (CHO) cells. Preferably, human embryonic kidney cell line 293 is used for expression of Hu-Asp proteins.

The choice of a suitable expression vector for expression of the Hu-Asp polypeptides of the invention will of course depend upon the specific mammalian host cell to be used, and is within the skill of the ordinary artisan. Examples of suitable expression vectors include pcDNA3 (Invitrogen) and pSVL (Pharmacia Biotech). A preferred vector for expression of Hu-Asp polypeptides is pBK-CMV (Stratagene). Expression vectors for use in mammalian host cells may include transcriptional and translational control sequences derived from viral genomes. Commonly used promoter sequences and enhancer sequences which may be used in the present invention include, but are not limited to, those derived from human cytomegalovirus (CMV), Adenovirus 2, Polyoma virus, and Simian virus 40 (SV40). Methods for the construction of mammalian expression vectors are disclosed, for example, in Okayama and Berg (*Mol. Cell Biol.* 3:280 (1983)); Cosman *et al.* (*Mol. Immunol.*

23:935 (1986)); Cosman *et al.* (*Nature* 312:768 (1984)); EP-A-0367566; and WO 91/18982.

The polypeptides of the present invention may also be used to raise polyclonal and monoclonal antibodies, which are useful in diagnostic assays for detecting Hu-Asp polypeptide expression. Such antibodies may be prepared by conventional techniques. See, for example, *Antibodies: A Laboratory Manual*, Harlow and Land (eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1988); *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Kennet *et al.* (eds.), Plenum Press, New York (1980).

The Hu-Asp nucleic acid molecules of the present invention are also valuable for chromosome identification, as they can hybridize with a specific location on a human chromosome. Hu-Asp1 has been localized to chromosome 21, while Hu-Asp2 has been localized to chromosome 11. There is a current need for identifying particular sites on the chromosome, as few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region can then be identified through linkage analysis, wherein the coinheritance of physically adjacent genes is determined. Whether a gene appearing to be related to a particular disease is in fact the cause of the disease can then be determined by comparing the nucleic acid sequence between affected and unaffected individuals.

In another embodiment, the invention relates to a method for the identification of an agent that increases the activity of a Hu-Asp polypeptide selected from the group consisting of Hu-Asp1, Hu-Asp2(a), and Hu-Asp2(b), the method comprising

- (a) determining the activity of said Hu-Asp polypeptide in the presence of a test agent and in the absence of a test agent; and
- (b) comparing the activity of said Hu-Asp polypeptide determined in the presence of said test agent to the activity of said Hu-Asp polypeptide determined in the absence of said test agent;

whereby a higher level of activity in the presence of said test agent than in the absence of said test agent indicates that said test agent has increased the activity of said Hu-Asp polypeptide.

FIGURE 2

10 30 50  
 ATGGCCCAAGCCCTGCCCTGGCTCCTGCTGGATGGGCGCGGAGTGCTGCCTGCCAC  
 5 M A Q A L P W L L L W M G A G V L P A H  
 70 90 110  
 GGCACCCAGCACGGCATCCGGCTGCCCTGCGCAGCGGCTGGGGGGCGCCCCCTGGG  
 G T Q H G I R L P L R S G L G G A P L G  
 130 150 170  
 CTGGCGCTGCCCCGGAGACCGACGAAGAGCCCGAGGAGCCCGCGGAGGGGAGCTTT  
 10 L R L P R E T D E E P E P G R R G S F  
 190 210 230  
 CTGGAGATGGTGGACAACCTGAGGGGCAAGTCGGGGCAGGGCTACTACGTGGAGATGACC  
 V E M V D N L R G K S G Q G Y Y V E M T  
 250 270 290  
 GTGGGCAGCCCCCGCAGACGCTCAACATCCTGGTGGATACAGGCAGCAGTAACCTTGCA  
 V G S P P Q T L N I L V D T G S S N F A  
 310 330 350  
 GTGGGTGCTGCCCCCACCCTTCCTGCATCGCTACTACCAGAGGCAGCTGTCCAGCACA  
 20 V G A A P H P F L H R Y Y Q R Q L S S T  
 370 390 410  
 TACCGGGACCTCCGAAGGGTGTGTATGTGCCCTACACCCAGCGCAACTGGGAAGGGGAG  
 Y R D L R K G V Y V P Y T Q G K W E G E  
 430 450 470  
 CTGGGCACCGACCTGGTAAGCATCCCCATGGCCCCAACGTCACTGTGCGTGCCAAACATT  
 25 L G T D L V S I P H G P N V T V R A N I  
 490 510 530  
 GCTGCCATCACTGAATCAGACAAGTTCTTCATCAACGGCTCCAACTGGGAAGGCATCCTG  
 A A I T E S D K F F I N G S N W E G I L  
 550 570 590  
 30 GGGCTGGCCTATGCTGAGATTGCCAGGCTTTGTGGTGTGGCTTCCCTCAACAGTCT  
 G L A Y A E I A R L C G A G F P L N Q S  
 610 630 650  
 GAAGTCTGCCCTCTGTGGAGGGAGCATGATCATTTGGAGGTATCGACCACTCGCTGTAC  
 35 E V L A S V G G S M I I G G I D H S L Y  
 670 690 710  
 ACAGGCAGTCTCTGGTATACACCCATCCGGCGGGAGTGGTATTATGAGGTGATCATTTGTG  
 T G S L W Y T P I R R E W Y Y E V I I V  
 730 750 770  
 CGGGTGGAGATCAATGGACAGGATCGAAAATGGACTGCAAGGAGTACAATATGACAAG  
 40 R V E I N G Q D L K M D C K E Y N Y D K  
 790 810 830  
 AGCATTGTGGACAGTGGCACCACCAACCTTCGTTTGGCCCAAGAAAGTGTGTTGAAGCTGCA  
 S I V D S G T T N L R L P K K V F E A A  
 850 870 890  
 45 GTCAATCCATCAAGGCAGCCTCCTCCACGGAGAAGTTCCTGATGGTTTCTGGCTAGGA  
 V K S I K A A S S T E K F P D C F W L G  
 910 930 950  
 GAGCAGCTGGTGTGCTGGCAAGCAGGCACCACCCCTTGGAAACATTTTCCAGTCATCTCA  
 50 E Q L V C W Q A G T T P W N I F P V I S  
 970 990 1010  
 CTCTACCTAATGGGTGAGGTACCAACCAGTCTTCCGCATCACCATCCTTCCGCAGCAA  
 L Y L M G E V T N Q S F R I T I L P Q Q  
 1030 1050 1070  
 55 TACCTGCGGCCAGTCCAAGATGTGGCCACGTCCCAAGACGACTGTTACAAGTTTGCCATC  
 Y L R P V E D V A T S Q D D C Y K F A I  
 1090 1110 1130  
 TCACAGTCATCCACGGGCACTGTTATGGGAGCTGTTATCATGGAGGGCTTCTACGTGTG  
 S Q S S T C T V M G A V I M E G F Y V V  
 1150 1170 1190  
 60 TTGATCGGGCCGAAAACGAATTGGCTTGTGCTGACGGCTTGCCATGTGCAGATGAG  
 F D R A R K R I G F A V S A C H V H D E  
 1210 1230 1250  
 TTCAGGACGGCAGCGGTGGAAGGCCCTTTTGTACCTTGGACATGGAAGACTGTGGCTAC  
 65 F R T A A V E G P F V T L D M E D C G Y  
 1270 1290 1310  
 AACATTCCACAGACAGATGAGTCAACCTTCATGACCATAGCCTATGTCATGGCTGCCATC  
 N I P Q T D E S T L M T I A Y V M A A I  
 1330 1350 1370  
 70 TGGCCCTCTTCATGCTGCCACTCTGCCCTCATGGTGTGTGAGTGGCGCTGCCCTCGCTGC

C A L F M L P L C L M V C Q W R C L R C  
 1390 1410 1430  
 CTGCGCCAGCAGCATGATGACTTTGCTGATGACATCTCCCTGCTGAAGTGAGGAGGCCCA  
 L R Q Q H D D F A D D I S L L K  
 5 1450 1470 1490  
 TGGGCAGAAGATAGAGATTCCCCCTGGACCACACCTCCGTGGTTCACTTTGGTCACAAGTA  
 1510 1530 1550  
 GGAGACACAGATGGCACCTGTGGCCAGAGCACCTCAGGACCCCTCCCCACCCACCAATGC  
 1570 1590 1610  
 10 CTCTGCCCTTGATGGAGAAGGAAAAGCCTGGCAAGGTGGTTCCAGGGACTGTACCTGTAG  
 1630 1650 1670  
 GAAACAGAAAAGAGAAGAAAGAAGCACTCTGCTGGCGGAATACTCTTGGTCACCTCAAA  
 1690 1710 1730  
 TTTAAGTCGGGAAATTCCTGCTCCTTCAAACCTTCAGCCCTGAACCTTTGTCCACCATTCCT  
 1750 1770 1790  
 15 TTAAATTCCTCAACCCAAAGTATTCTTCTTTTCTTAGTTTCAGAAGTACTGGCATCACAC  
 1810 1830 1850  
 GCAGGTTACCTTGGCCTCTCTCCCTGTGGTACCCTGGCAGAGAAGAGACCAAGCTTGTTT  
 1870 1890 1910  
 20 CCCTGCTGGCCAAAGTCAGTAGGAGAGGATGCACAGTTTGCTATTGTCTTTAGAGACAGG  
 1930 1950 1970  
 GACTGTATAAACAAGCCTAACATTGGTGCAAAGATTGCCTCTTGAAAAAAAAAAAAA



FIGURE 3

10 30 50  
 5 ATGGCCCAAGCCCTGCCCTGGCTCCTGCTGGSATGGCGCGGGAGTGTGCCTGCCAC  
 M A Q A L P W L L L W M G A G V L P A H  
 70 90 110  
 GGCACCCAGCACGGCATCCGGCTGCCCTGCGCAGCGGCTGGGGGGCGCCCCCTGGGG  
 G T Q H G I R L P L R S G L G G A P L G  
 130 150 170  
 10 CTGGCGCTGCCCCGGGAGACCGACGAAGAGCCCGAGGAGCCCGCGGAGGGGAGCTTT  
 L R L P R E T D E E P E E P G R R G S F  
 190 210 230  
 GTGGAGATGGTGGACAACCTGAGGGGCAAGTCGGGGCAGGGCTACTAGTGGAGATGACC  
 V E M V D N L R G K S G Q G Y Y V E M T  
 250 270 290  
 15 GTGGGCAGCCCCCGCAGACGCTCAACATCCTGGTGGATACAGGCAGCAGTAACCTTGCA  
 V G S P P Q T L N I L V D T G S S N F A  
 310 330 350  
 GTGGGTGCTGCCCCCACCCTTCTGCTGCTACTACCAGAGGCAGCTGTCCAGCACA  
 V G A A P H P F L H R Y Y Q R Q L S S T  
 370 390 410  
 20 TACCGGGACCTCCGGAAGGGTGTGTATGTGCTTACACCCAGGCAAGTGGGAAGGGAG  
 Y R D L R K G V Y V P Y T Q G K W E G E  
 430 450 470  
 25 CTGGGCACCGACCTGGTAAGCATCCCCATGGCCCCAACGTCACTGTGCGTCCCAACATT  
 L G T D L V S I P H G P N V T V R A N I  
 490 510 530  
 GCTGCCATCACTGAATCAGACAAGTTCTTCATCAACGGCTCCAACCTGGGAAGGCATCCTG  
 A A I T E S D K F F I N G S N W E G I L  
 550 570 590  
 30 GGGCTGGCCTATGCTGAGATTGCCAGGCGCTGACGACTCCCTGGAGCCTTTCTTTGACTCT  
 G L A Y A E I A R P D D S L E P F F D S  
 610 630 650  
 35 CTGGTAAAGCAGACCCACCTTCCCAACCTCTTCTCCCTGCAGCTTTGTGGTGTGGCTTC  
 L V K Q T H V P N L F S L Q L C G A G F  
 670 690 710  
 CCCCTCAACCACTCTGAAGTGTGCTGGCCTCTGTGCGAGGGAGCATGATCATGGAGGTATC  
 P L N Q S E V L A S V G G S M I I G G I  
 730 750 770  
 40 GACCACTCGCTGTACACAGGCAGTCTCTGCTATACACCCATCGGGCGGAGTGGTATTAT  
 D H S L Y T G S L W Y T P I R R E W Y Y  
 790 810 830  
 GAGGTCACTATTGTGCGGGTGGAGATCAATGGACAGGATCTGAAATGGACTGCAAGGAG  
 E V I I V R V E I N G Q D L K M D C K E  
 850 870 890  
 45 TACAATATGACAAGAGCATTGTGGACAGTGGCACCACCAACCTTCGTTTGGCCCAAGAAA  
 Y N Y D K S I V D S G T T N L R L P K K  
 910 930 950  
 50 GTGTTTGAAGCTGCAGTCAAAATCCATCAAGGCAGCCTTCTCCACGGAGAAGTTCCCTGAT  
 V P E A A V K S I K A A S S T E K F P D  
 970 990 1010  
 GGTTCCTGGCTAGGAGAGCAGCTGGTGTGCTGGCAAGCAGGCACCACCCCTTGAACATT  
 G F W L G E Q L V C W Q A G T T P W N I  
 1030 1050 1070  
 55 TCCCACTCACTCTACTCTACCTAATGGGTGAGGTACCAACCACTCTCCGCATCACC  
 F P V I S L Y L M G E V T N Q S F R I T  
 1090 1110 1130  
 ATCCTTCCGCAGCAATACCTGCGGCCAGTGGGAAGATGTGGCCACGTCCCAAGACGACTGT  
 I L P Q Q Y L R P V E D V A T S Q D D C  
 1150 1170 1190  
 60 TACAAGTTTGGCATCTCACAGTCATCCAGGGCACTGTTATGGAGCTGTTATCATGGAG  
 Y K F A I S Q S T G T V M G A V I M E  
 1210 1230 1250  
 65 GGCTTCTACGTTGTCTTTGATCGGGCCGAAAACGAATTGGCTTTGCTGTCAGCGCTTGC  
 G F Y V V P D R A R K R I G F A V S A C  
 1270 1290 1310  
 CATGTGCACGATGAGTTTACGACGGCAGCGGTGGAAGGCCCTTTGTACCTTGGACATG  
 H V H D E F R T A A V E G P F V T L D M  
 1330 1350 1370  
 70 GAAGACTGTGGCTACAACATTCCACAGACAGATGAGTCAACCTCATGACCATAGCCTAT

E D C G Y N I P Q T D E S T L M T I A Y  
1390 1410 1430  
GTCATGGCTGCCATCTCGCCCTCTTCATGCTGCCACTCTGCCTCATGGTGTGTCAGTGG  
V M A A I C A L F M L P L C L M V C Q W  
1450 1470 1490  
5 CGCTGCCCTCCGCTGCCTGCCAGCAGCATGATGACTTTGCTGATGACATCTCCCTGCTG  
R C L R C L R Q Q H D D F A D D I S L L  
1510 1530 1550  
AAGTGAGGAGGCCCATGGGCAGAAGATAGAGATTCCCTGGACCACACCTCCGTGGTTCA  
10 K  
1570 1590 1610  
CTTTGGTCACAAGTAGGAGACACAGATGGCACCTGTGGCCAGAGCACCTCAGGACCCTCC  
1630 1650 1670  
CCACCCACCAAATGCCTCTGCCTTGATGGAGAAGGAAAAGGCTGGCAAGGTGGGTTCCAG  
15 GGACTGTACCTGTAGGAAACAGAAAAGAGAAGAAAGCACTCTGCTGCCCGCAATACT  
1690 1710 1730  
CTTGGTCACCTCAAATTTAAGTCGGGAAATTCTGCTGCTTGAAACTTCAGCCCTGAACCT  
1750 1770 1790  
20 TTGTCCACCATTCCTTTAAATTCTCCAAACCCAAAGTATTCTTCTTTCTTAGTTTCAGAA  
1810 1830 1850  
GTACTGGCATCACACGCAGGTTACCTTGGCGTGTGTCCTGTGGTACCTGGCAGAGAAG  
1870 1890 1910  
AGACCAAGCTTGTTTCCCTGCTGGCCAAAGTCAGTAGCAGAGGATGCACAGTTTGCTATT  
1930 1950 1970  
25 TGCTTTAGAGACAGGGACTGTATAAACAAGCCTAACATTGGTGCAAAGATTGCCTCTTGA  
1990 2010 2030  
2050 2070  
ATTAAAAAAAAAAAAAAAAAAAAAAAAA

# Exhibit C

coding sequence of Hu\_Asp-1 has been prepared and the predicted amino acid sequence, aligned with both the short and long forms of Hu\_Asp-2, is attached. This splice variant of Hu\_Asp-1 encodes a 521 amino acid polypeptide including a 27 residue signal peptide so the pro-form of the enzyme contains 76 amino acid residues upstream of the first active site motif. This upstream sequence also contains a third DSG motif. Alignment of the sequence surrounding this upstream DSG with the ProSite motif for aspartyl proteases revealed a poor match while the other two DTG/DSG motifs showed a good match. Alignment, with Hu\_Asp-2 sequences using the Clustal W algorithm highlights two major differences between Hu\_Asp-1 and Hu\_Asp-2; the NH<sub>2</sub> terminal extension in Hu\_Asp-1 is much longer and that Hu\_Asp-1 appears to be more like the long form of Hu\_Asp-2. The longest stretches of amino acid identity align with the two aspartyl protease active site motifs although other areas of conservation are also scored.

Finally, the Hu\_Asp-1 gene was localized to human Chromosome 21 by hybridization to a Southern blot containing a series of mouse/human or hamster/human somatic cell hybrids (attached).

**Hu\_Asp-2**, Mary provided an inventory of the expression constructs for Hu\_Asp-2 (attached). The entire ORF of both the short (438) and long forms (269) of Hu\_Asp-2 have been engineered into the mammalian cell expression vector pBK-CMV. Also, both the short


and long forms, with the COOH-terminal transmembrane domain deleted, have been prepared as NH<sub>2</sub> terminal 6His-fusions in the *E. coli* expression vector pQE30. Finally, the entire ORF from the short form of Hu\_Asp-2 has been cloned downstream of the ecdysone-inducible promoter in the vector pIND and in a polycistronic fusion with GFP (pIRESGFP) for mammalian cell expression studies.

**Hu\_Asp-3 and Hu\_Asp-4**— Queries of the LifeSeq Assembled database with the sequences of either Hu\_Asp-1 or Hu\_Asp-2 identified (1) gene bins with exact matches to the query sequences, (2) gene bins matching the 5 known human aspartyl proteases [pepsinogen A, pepsinogen C, cathepsin D, cathepsin E and renin], and (3) three gene bins with significant homology [242842, 242824, 39511], in descending order of significance. Translation of the longest assembled templates contained within these gene bins revealed that they each encoded polypeptides containing the duplicated active site motif that is the hallmark of mammalian aspartyl proteases. Alignment of the predicted amino acid sequences for templates 451054.3 and 451034.4 showed that they were very similar with approximately 90% sequence identity at the amino acid level (attached). Template 126360 was most related to 451054.3 and 451034.4, with approximately 70% shared identity. Consistent with the nomenclature initiated previously, the genes represented by Incyte templates 451054.3, 451034.4, and 126360 are referred to as Hu\_Asp-3, Hu\_Asp-4a and Hu\_Asp-5, respectively. Template 451034.2 appeared to be a splice variant of 451034.4 with a 25 amino acid (75 bp) insertion near the CO<sub>2</sub>H-terminus (data not shown). The cDNAs that defined the 5'-most sequence of each of these templates were identified, obtained for sequence analysis and determination of the tissue distribution of expression of transcripts derived from these genes. The Hu\_Asp-3 probe visualized a single 1.6 kb transcript that showed a limited expression pattern that was expressed at the highest levels in lung, immunological tissues (spleen, thymus and PBLs), and kidney (attached). No expression of Hu\_Asp-3 transcripts was detected in whole brain while a weak signal was observed in several brain regions including the medulla, spinal cord and putamen (attached). These results were consistent with the expression pattern determined by EST sequencing in LifeSeq Assembled (39 ESTs) which indicated highest expression in the hematopoietic/immune category (41%) and the nervous category being the second highest (16%). The Hu\_Asp-4 p visualized a similar pattern of transcript size and abundance except that the signal was most in lung tissue. No transcripts were detected in either whole brain or selected brain regions under conditions used in these experiments. A survey of expression using LifeSeq Assembled (1) indicated that 93% of the ESTs that comprise the Hu\_Asp-4 template were derived from r

# Exhibit D


# Asp2 $\rightarrow$ Baculovirus Expression

Engineer the pre-pro form of Asp2<sup>+</sup> TM for expression in Baculovirus using the Vector pVL1393



BAM Kozak  
GGATCC GCC ACC ATG GCC  
G S S T M A Q A L...

PCR: 100ng pDNA3.1 kbp Asp2 (B) 1  $\mu$ l  
8  $\mu$ l dNTPs  
5  $\mu$ l Pfu  
1.5 Asp2BAM  
(x2) or Asp2not-tm 1.5 Asp2-not  
1 Pfu  
32 H<sub>2</sub>O



Extract, ppt Digest w/ 83  $\mu$ l H<sub>2</sub>O  
10  $\mu$ l 10x  $\neq$  3 37°C  
4  $\mu$ l Bam  
3  $\mu$ l Not

asp2Bam OGC TTT GGA TCC Kozak GCC ACC ATG GCC CAA GCC CTG CCC TGG  
BAM S T M A Q A L P W  
asp2not-tm OGC TTT GCGGCGGC CTA TGA CTC ATC TGT CTC TGG AAT GTT G  
Not \* S E D T Q = reverse complement  
asp2not OGC TTT GCGGCGGC TCA CTT CAG CAG GGA GAT GTC ATC  
Not \* K L L S I = reverse complement

Run 1% prep gel



Geneclon frags.  
Set up ligation o/p

①  
Asp2/BAM-Not (100ng) = 1  $\mu$ l 83  
pVL1393 (100ng) 4  $\mu$ l 19  $\mu$ l

②  
Asp2-tm/BAM Not 130ng = 2  $\mu$ l  
pVL1393 100ng = 4  $\mu$ l

14°C o/p

Read and understood by me

SW

Date

TF DHS<sub>2</sub> w/ 2 $\mu$ l Plate on LB-Amp

Pick CEUS ~~#1-8~~ for long form — tm had no CEUs (#1-8)

PCR w/ Asp2-1  $\rightarrow$  Asp2-4

See p. 114 — looks good! (#7)

Plate total — tm + f

No — tm if's  $\therefore$  ck frag opn @ gel — lighter than expect — Set up new ligation.


— tm ligation: 2 $\mu$ l pVL1393 (80ng)  
 1 $\mu$ l Asp2 — tm (~55ng) } 14°C o/n  
 1 $\mu$ l 10x  
 1 $\mu$ l ligase

TF DHS<sub>2</sub> w/ 2 $\mu$ l plate on LB-Amp

Pick 28 CEUs & PCR w/ Asp2-1 & Asp2-4 (427bp)

Asp2 — tm pVL1393 Big PCR  
 Asp2-1  $\rightarrow$  2-4

Pick #2 for Cs prep — MJB



Harvested Cs preps — lots of debris in tubes  
 Extract, dialyze etc.

Conc. by OD:

Asp2 pVL1393 = 1.37  $\mu$ g/ $\mu$ l

Asp2 ATM pVL1393 = 0.93  $\mu$ g/ $\mu$ l

Just digest w/ BAM + Not @ 37°C o/n

Given to D. Fisher for  
 Baculo expression & Roger  
 for Seq. confirmation

Seq of  $\pm$  TM constructs  
 is correct (1 nt change that  
 is silent)

Read and understood by me

Date

SW

# Exhibit E



- We have previously prepared Asp2<sup>±</sup>TM (full length-signal, proct) in the baculovirus expression vector pVL1393.

- We have received the first clones for Asp1+TM & Asp2+TM. Asp1 has been analysed by PAGE & Western. There is a lot of protein being produced & is associated with the SF9 cells. At this stage we can't say if the signal sequence is being clipped, if it's membrane associated or free in the cytosol.
- Anticipating difficulty in the purification of a non-secreted, non-tagged protein, I will design primers that incorporate a C-term to His. The primers will be as per #105 NFE2B3 31942 w/ 6 His added.

Asp2net — 6His : Cgc TTT gLgagccgc CTA-(ATg)16-TgA-CTC  
ATC-TgT-CTg-Tgg-AAT-gTT-g

Asp2met His:  $\text{Cgc TTT ggc ggc}^{\text{NOT}} \text{-TCA- (ATg)}^{\text{x}} \text{x6-CTT-CAg-CAg-gga gat-}$   
 $\text{gtc-ATC}$  K L L S E

ASP2NOT-TIME  
ASP2NOT-MS

T7829-001	69	DET	0.30	185.15.8	91.6	32.6	24.6	807.9	43.6	Moderate	No	CGCTTTTCGGGCGCCCTCATGAT
-----------	----	-----	------	----------	------	------	------	-------	------	----------	----	---

PCR 100 ng 1  $\mu$ l of Asp2pcDNA3.1hygro<sup>+</sup>®

$$32 \text{ mol H}_2\text{O}$$

8.1 dNTR

5.  $10 \times$  buffer

1.5 ml Asp2 Base

1.5ml Asp2not - 1mM His or Asp2not His

1st Prize I

XZ

15 copies

9700

Extract: ppt rxns. Resuspend  $\pm$  in 4/100  $H_2O$

4/22/0

$$5 \times 10^8 \approx 3$$

2nd Bar


Ziel Not

37°E

— 94 —

Read and endorsed by

Run 1% agarose prep gel



Cut out fragments & ignore


Conc by OD =  
Asp2 - dm His = 80 ng/l  
Asp2 + dm His = 60 ng/l

ligations: 120 ng pVh1393 / Not Bam = 3  $\mu$ l  
Asp2 insert 2  $\mu$ l  
10x buffer 1  
T4 ligase 1  
H<sub>2</sub>O 3

16°C o/n


TF DH5 w/ 2  $\mu$ l. Plate 200  $\mu$ l on hBr Amp - dm @ 37°C o/n

Good # of CFUs over background - Pick 7 CFU / construct & PCR w/ Asp2 (2-5) to yield @ ~ 440 bp frag



Nice Neg Control for the - dm's - the primer (Asp2-2) is in the TM - take a guess & pick #6 for each construct. Inoc 1 liter hBr Amp - dm @ 37°C o/n

Asp2 - dm His  
PRd: 2-70-Bam & 2-70-Sph



Work up std alkaline lysis preps. Banders Cs - also re PCR - dm bugs w/ new set of primers (2-70-Bam & 2-70-Sph). There are weak bands in 1, 5, 7 - I don't see anything in #6 but I'm hoping that is due to not having much to amplify in the PCR after using most of the 50  $\mu$ l for the inoculation.

Harvest nice plasmid bands, extract & dialyze / H<sub>2</sub>O o/n

Read and understood by me

Date

PLEASE LEAVE RED SPACES FOR MICROFILMING

Ppt & Resuspend in 1 ml H<sub>2</sub>O

Asp2 + tm His pVL1393 = 1.9 ng/μl

Asp2 - tm His pVL1393 = 2.3 ng/μl

Test digest 1 μl w/ 4 μl Bam + 4 μl Not in 100 μl IX #3 for  
~ 4 hrs @ 37°C

Asp2 + tm His pVL1393

Look good. Submit to DSC

+H1 = A (12r, 13f, 14f, 15r, 16f, 29f, 30r)  
-tm = B ( " " )

Note to BEVS to begin baculo expression  
Samples given to Ma hi to transfer  
to Merrill Radstock

Rec'd seq from Roger @ /DSC930-934

The Seq's are correct

Bam - Not sites intact

6xHis fused on C-terminal followed by STOP  
Alignment w/ 2R Seq - 100% identity except  
ambiguity that has always existed  
between 2R & SKR - Silent w/ no AA change

Read and understood by me

Date

PLEASE LEAVE RED SPACES FOR MICROFILMING

# Exhibit F

# Pro Asp2 pQE70 Analysis

See 31942 p. 145-148 for construction, etc.

4 CFUs from the Asp2 pQE70 mp #6 / M15(pREP) transformation were picked & grown & induced w/ 1mM IPTG.  
The induction was not obvious.

Next actions: Digest mp #6, looked ok. Send up for sequencing.  
Rerun more sample To/Ty on a 10 well gel.

Reran 10 µl of To/Ty samples after mechanically shearing w/ a 22g needle, followed by reboiling 5'. The induced time points pinched & smeared while the To's looked ok.  
Induction of a single band isn't obvious -  
The #6 mp DNA was submitted for Seq w/ 12r, 13f, 14f, 15r, 16f, pQE30r labeled Pro70  
- pQE70 forward (pQE promoter) primer was ordered.

Obtained preliminary Seq from Regza. There are 2 bp deleted & a substitution relative to the correct Seq.


Regza "found" the 2bp deletion - but the 1st substitution which changes N → T can't be read from either strand. Resubmit w/ primer #16f & give Regza 2x11 µl DNA so he can add some of his own Asp2 primers.

Jerry said the samples were dropped - resubmitted this (A.M.)

Even if there is an amino acid substitution, I should be making & inducing a protein since all is in frame w/out STOPS.

Roger left a message saying "It's an A" which makes

Read and understood by me




Date

the Seq [Correct]

Pick 9 CFU from Asp2<sup>#6</sup>QE70 [M15pREP] & PCR to verify inserts w/ 2-70-Spn & 2-70-Bam for 35 cycles.

Asp2pQE70 [M15pREP] 2-70-Spn & 2-70-Bam



All are positive as would be expected since the M15s were + w/ supercoiled mp #6 DNA.

Inoc 2x5 ml LB + 100 µg/ml Amp + 25 µg/ml Kan w/ #1-4 - Grow 2 1/2 hrs - Freeze 1x 5 ml aliquot

IPTG induce the other. (1 mM) for 3 hrs - Freeze culture

Grow cultures ck OD of 1 ml (\* = IPTG induced)

1	0.464	}	pellet 1 ml ~ 0.500
2	0.554		
3	0.475		
4	0.428		
*1	0.823	}	pellet 0.5 ml ~ 0.500
*2	0.895		
*3	0.928		
*4	0.921		

Resuspend in 50 µl  
E+SDS Δ100°C 5'  
Add 15 µl H<sub>2</sub>O  
25 µl 4X NuPAGE SB.  
10 µl reducing agent

Run 2 NuPAGE 10% MES gels w/ 10 µl of each sample  
marker 1 1\*, 2.2\* etc double marker.

Stain 1 gel in colloidal blue


Western blot 1 gel - probe w/ Pierce INDIA His-Probe Super Signal

Stain shows no obvious induction, but the His-probe clearly picks up an induced band in all 4 clones.

A very faint band can be seen that corresponds

CPZ

ProAsp2-TmpQE70 Expression in E.coli



inoc 400ml LB + Amp + Kan w/  
#1. Grow @ 37°C o/n

Draw 4 liters LB + Amp + Kan  
inoc each w/ 100ml o/n  
culture. Draw 2 1/2 hrs  
induce w/ IPTG to 1mM  
for 3 hrs

Spin down bugs & transfer to M. Fairbanks

Mike says he sees the His signal in the Soluble  
fraction - but at very low levels  
I'll try a time course to try & boost expression

In an effort to boost expression - Try a time course &  
Switch to clone #2

5ml LB + 25µg/ml Kan + 100µg/ml Amp

Inoc 8x5ml LB + 200µg/ml AMP + 25µg/ml Kan w/ 50µl o/n  
Grow @ 37°C 2 1/2 hrs

Induce 4x5ml w/ 1mM IPTG  
4x5ml w/ 2mM IPTG

Collect time points @ 1hr, 2hr, 4hr, o/n → Store on ice @ 4°C

ck OD A<sub>600</sub> of each culture. Pellet 100 of each &  
give to M. Fairbanks for analysis

M. Fairbanks reports no expression.

Now Henrikson reports that Jordan Jangp Colleagues

Read and understood by me

Date

*[Signature]*

have successfully expressed active Asp2 in E coli  
Suddenly the focus has shifted back to E coli expression

Trying to work w/ the ProATH pQE70 construct w/ have in hand  
& optimize expression:

TF ProAsp2pQE70\*6 mp DNA into XL-1 Blue MRE' Kan

DH5 F'1Q

Plate on LB+ Amp (100µg/ml) + Kan (10µg/ml) plates w/ incub @ 37°C  
o/n

Prepare:	LB-LS	LB-HS	2XYT	SuperBroth
Tryptone	10	10	16	35
Yeast Ex	5	5	10	20
NaCl	5	10	5	5

Pick 2 cells from each transformation → 50µl H<sub>2</sub>O

Aliquot 10µl to 10ml of each broth w/ incub @ 37°C w/  
Shaking After 8 hrs @ 37°C ck ODS

GAM

Bug	clone	broth	OD/ml	OD/ml induced
XL1 Blue	1	LB-LS	0.325	1.16
"	1	LB-HS	0.511	1.75 remove 0.5cd w/ incub
"	2	LB-LS	0.274	1.73 pellet in 2059 tube
"	2	LB-HS	0.391	1.74 Store @ 4°C o/n
DH5	1	LB-LS	0.345	1.67
"	1	HS	0.391	1.69 induce 5ml w/
"	2	LS	0.132	1.68 50µl 100mM IPTG
"	2	HS	0.103	1.70 (1mM) @ 30°C
XL1 Blue	1	2XYT	0.543	1.92
"	2	2XYT	0.430	1.92 o/n (14 1/2 hrs)
DH5	1	2XYT	0.483	1.89
"	2	2XYT	0.147	1.9
XL1 Blue	1	Super	0.617	1.99 Remove 0.5cd of
"	2	"	0.416	1.97 induced & pellet
DH5	1	"	0.413	1.99
"	2	"	0.116	1.94

Read and analyzed by

3/20/96

See p 69

Date

PLEASE LEAVE RED SPACES FOR MICROFILMING



Ppt, pellet resuspend in 82  $\mu$ l  $H_2O$   
10  $\mu$ l 10x #2 } 37°C o/n  
Read and understood by me 4  $\mu$ l Bam Date  
4  $\mu$ l Sph  
Also 3  $\mu$ g pQE70 in 4  $\mu$ l Sph

Run 17% prep gel - See p. 149

Deinuclear pQE70/Spn-Bam } Resuspend in 50  $\mu$ l  
 Asp2/Spn-Bam

Joao Asp2S - the seq has 2 nt dilutions per J. Slightam

it accidentally loaded these fragments back on a gel - cut out & hold @ 4°C

Deinuclear prep

ck conc of frag by OD

Asp2/Spn-Bam = 35 ng/ $\mu$ l

pQE70/Spn-Bam = 15 ng/ $\mu$ l

Ligation:

③	④	
70 ng Asp2 = 2 $\mu$ l	—	
90 ng pQE70 = 6	6	16°C o/n
10x buffer 1	1	
ligase 1	1	
H <sub>2</sub> O —	2	

Note

TF DH5 <sup>w/2  $\mu$ l</sup> because of the higher tf efficiency - then

Re-transform later into (M15pREP3)

Plate 200  $\mu$ l on LB-Amp - Inc @ r.t for the weekend

Only 6 CFU - Pick & PCR w/ Spn-Bam PCR primers.

Pro Asp2 pQE70  
 2:70-Spn-2:70-Bam  
 7 8 9 10 11 12

No inserts!

Start Again w/ the PCR 100 ng Asp2 pcDNA3.1  $\mu$ l

dNTPs 8

10x buffer 5

2:70-Spn 1.5

2:70-Bam 1.5

x2

15 cycles

Read and understood by me

SIX

Pwo | Date

H<sub>2</sub>O 32

Extract & ppt rns. Resuspend in 41  $\mu$ l H<sub>2</sub>O, 5  $\mu$ l 10x #2, 2  $\mu$ l Sph, 2  $\mu$ l Bam

Also Digest more pQE70: 5  $\mu$ l = 10  $\mu$ l

10x #2 5

Bam 2

Sph 2

H<sub>2</sub>O 31

Asp2 Pst pQE70  
Sph-Bam Sph-Bam



inc @ 37°C o/n

Del purify w/ gene clean


Conc by OD = pQE70/Sph-Bam = 40 ng/ $\mu$ l  
pro Asp2/ " = 20 ng/ $\mu$ l

Ligations: 2  $\mu$ l pQE70 = 80 ng  
1  $\mu$ l 10x  
1  $\mu$ l ligase  
1  $\mu$ l pro Asp2

TF DH5 w/ 2  $\mu$ l. Plate 200  $\mu$ l on LB+AMP

High background. Pick 14 CEUs & DCP w/ Asp2 (2-5) to produce @ ~440 bp product.


PCR: Asp2 (2-5)



Nice Neg Control! The primer pair I chose for PCR included the TM.  $\therefore$  these CEUs may not be neg. Repeat using 2-70-Sph & 2-70-Bam

PCR: 2-70-Bam  
2-70-Sph

Pro Asp2 pQE70



Faint bands in #6 & #7  
since 5  $\mu$ l gel  
w/ #6, #7 for  
mini preps

Read and understood by me

Date

JM

Work up std alkaline lysis mini prep from 1 1/2 mls. Resuspend in 100  $\mu$ l  $H_2O$

Just digest 5  $\mu$ l w/   
 6  $\mu$ l 10x #2   
 2  $\mu$ l Sph I   
 2  $\mu$ l Bam HI   
 45  $\mu$ l  $H_2O$  } 2 hrs @ 37°C

#6 looks ok. <sup>all but light</sup> Tf M15 (pREP) 200  $\mu$ l w/   
 ~0.5  $\mu$ l of #6 & #7. Plate 50  $\mu$ l   
 on LB + Amp + 25  $\mu$ g/ml Kan. incub @ 37°C q/n

Pick 4 CFU & inoc 5 ml LB + Amp + Kan a/w   
 inoc 10 ml LB + Amp + Kan w/ 500  $\mu$ l of each a/w   
 Grow ~ 2 hrs to O.D 0.5 - 0.7

To 1 0.555 OD/ml   
 2 0.57   
 3 0.741   
 4 0.653 } pellet 1.00 - Store @ -20°C

Add IPTG to 1 mM & Continue Growth @ 37°C. Measure OD @ 2 hrs

T<sub>2</sub> 1. 1.119   
 2. 1.144   
 3. 1.267   
 4. 1.177 } pellet 1.00   
 Store -20°C

T<sub>4</sub> 1. 1.386   
 2. 1.434   
 3. 1.464   
 4. 1.275 } pellet 1.00 &   
 Store @ -20°C

Resuspend 100 equiv's in 65  $\mu$ l Et/SDS.  $\Delta$  100°C 2". Add 25  $\mu$ l Novex 4x S.B.E.   
 10  $\mu$ l reducing agent  $\Delta$  70°C 10'

Run a 15 well NuPAGE gradient gel - loading the 5  $\mu$ l was very difficult   
 due to stringy viscosity (DNA?) Stain gel in Colloidal blue   
 Nothing jumps right out & the loads seem light.

For further analysis See 32587 p. 31

# Exhibit G

Transfection of Sf9 cells with Asp2 $\Delta$ TM

(from Bienkowski's lab)

- (1) Use  $2 \times 10^6$  Sf9 cells for transfection.
- (2) Add 0.5  $\mu$ s of virus DNA and 2  $\mu$ s of transfer DNA.
- (3) Incubate at 27°C for 4 hr.
- (4) Add 4 ml of TBM medium and keep at 27°C for 5 more days.

I did co-transfection today, and the cells were incubate at 27°C for 5 more days.

Transfection stock was harvested and labeled this morning and it was stored at 4°C.

I did plaque assay today with 6 dilutions of the transfection stock. The plates were kept at 27°C for 6 to 10 more days.

Five clones were picked up and 5 ml of TBM medium was added into each clone. They will culture for 3 days at 27°C.

The 1st Amp stock was harvested and labeled this morning. It was stored at 4°C.

I did 2nd Amp today and it were kept at 27°C

Read and understood by me

S.K. Rockbach

Date

for 64 hr.

Harvested all 5 clones this morning. They were labeled as 2nd Amp stocks and stored at 4°C. Mike came over to pick up both pellets & supts of all 5 clones for assay.

Mike sent me a note saying there is no expression in all 5 clones. He asked to repeat the small infection in the serum free medium, he will assay them again.

I asked Jerome to repeat the small infection of all 5 clones in the serum free medium for Mike.

Jerome told me that after small infection in the serum free medium, Mike chose clone #1 for making a 100 ml of prep.

Read and understood by me

S. K. Rockumbach

Date

# Exhibit H



## Expression Analysis of BVES-1<sup>tr</sup> Asp2L<sup>Δ</sup>TM

Purpose: I previously analyzed the analytical scale sf9 cell infections w/ pVL1393/HuAsp2L<sup>Δ</sup>TM and concluded that (1) Clone #1 was best for scale-up & (2) it appears that little if any of the target protein is secreted into the medium.

### Experimentals

#### (1) More detailed analysis of the Conditioned Medium

Inspection of the WB's of the concentrated conditioned medium did reveal a weakly stained band @ ~65kDa that did not appear in the sf9 control (although this may have been due to variable serum content). Since the large albumin band might obscure any secreted Asp2L<sup>Δ</sup>TM, I decided to fractionate and the Asp2L<sup>Δ</sup>TM content of the medium may be too low to readily detect by WB analysis, I decided to fractionate the CM.

The protein content of the conditioned medium was quantified using the BioRad method and the results are summarized below.

CM Sample	A <sub>595</sub> (25 $\mu$ l)	$\mu$ g/ $\mu$ l	Total (mg)
sf9 control	0.135	0.18	3.1
AcNPV-CDK5-3	0.132	0.17	7.3
Hu Asp2L <sup>Δ</sup> TM	0.119	0.16	7.2

Two aliquots of AcNPV-CDK5-3 and the Asp2L<sup>Δ</sup>TM conditioned medium were dialyzed against 4L (2x) 25mM NaOAc (4.5) pH 4.0 @ 4°C. This resulted in some ppt so the solutions were clarified by centrifugation (3000rpm / 15') & the protein assay repeated.

Sample	Suspension	Super.
AcNPV-CDK5-3	0.119 / 0.16 $\mu$ g/ $\mu$ l	0.041 / 0.06 $\mu$ g/ $\mu$ l
Hu Asp2L <sup>Δ</sup> TM	0.092 / 0.13 $\mu$ g/ $\mu$ l	0.039 / 0.06 $\mu$ g/ $\mu$ l
	3.5 mg total	1.3 mg
	2.8 mg total	1.3 mg

Read and understood by me

Date

Based on the protein assay, the recovery following dialysis is as follows:

$$\text{A-CDK5-3} \quad 1.3 \text{ mg} / 3.5 \text{ mg} \times 100 = 37\%$$

$$\text{Hic Asp2L STM} \quad 1.3 \text{ mg} / 3.2 \text{ mg} \times 100 = 40\%$$

The clarified supernatants were chromatographed on a MonoS column equilibrated in 25 mM NaOAc (4.5) as follows:

$$\text{PR} = 1.0 \text{ ml/min}$$

$$\text{Sample Load} \approx 22 \text{ nls}$$

$$\text{Elution} \quad 0 \rightarrow 100\% \text{ B, } 50' \text{ where } A = 25 \text{ mM NaOAc (4.5)}$$

$$B = \text{1.0 M NaCl}$$

The elution profile was monitored @ 280 nm (0.05 AUFS) & 1.0 ml fractions were collected for further analysis.

16.25  $\mu$ l samples were taken for NuPAGE gel analysis as usual;

$\rightarrow$  1x Loading buffer + DTT + sample  $\xrightarrow{70^\circ \text{C } 10 \text{ min}} \xrightarrow{10 \text{ min}} 4-12\% \text{ gradient gels (15 wells)}$

$\rightarrow$  1x MB RB / ET, 90' @ 35V

$\rightarrow$  WB - 1/1000 dil U191TB #4

- 1/1000 dil F2R (AP)

- NBT / BCIP

A second gel / WB was run (based on the first gels) to reanalyze the following samples on a 10 well / 10% gel

1. CHO Asp2L #5 (20)

2. CHO-BVES Asp2L STM

3. " " " pH 4.5

4. Mono S #10

5. Mono S #12

6. " #14

7. " #16

8. CHO (cdk5) cont

9. CHO (cdk5) control pH 4.5

Read and understood by me

Date

## Results:

Aliquots of conditioned medium obtained from sf9 cell infections w/ recombinant bV containing the Asp2L ATM or a control gene (Cdk5-3) were analysed for the presence of Asp2L ATM protein, before & after chromatography on Mono S. Dialysis of the conditioned medium against NaCl buffer pH 4.5 led to protein ppt of  $\sim 2/3$  of the original protein. The supernatant was fractionated by Mono S chromatography & the elution profiles monitored by  $A_{280nm}$  absorbance & WB analysis. Both CM samples showed similar behavior, summarized below:

- \*  $\sim 2/3$  of starting protein ppt upon dialysis
- \* large  $A_{280}$  in unbound fraction of Mono S
- \* similar  $A_{290}$  fingerprint during the gradient elution.

To determine which fractions contained Asp2, aliquots were analysed by WB analysis & the results are summarized below:

- \* Conditioned Medium  $\sim 45kDa$  immunoreactive band
- \* Dialysed CM (Super)  $\sim 43kDa$  " "
- \* PPT from Dialysis - blank
- \* Mono S column fractions - maybe immunoreactivity in #12

band (immunoreactive) size decreased following dialysis -  
? Activation ??

## 2<sup>nd</sup> Analysis

- \* BIES-EM Asp2L ATM  $\rightarrow$  immunoreactive band @  $52kDa$  that is not in the control
- \* Seems like Asp2L ATM IS going away w/ time @ loss in bV
- \* BIES-EM Asp2L ATM / pH 4.5  $\rightarrow$  immunoreactive band @  $\sim 50kDa$ , but much lighter than before (not in control)
- \* Lack of core in col. \* faint immunoreactive band in #12/14

Read and understood by me

Date

# Exhibit I

## Continued Analysis of BUES-Hu Asp2L STM Conditioned Medium

Purpose: To determine if purification of the protein by an ion exchange chromatography followed by activation at low pH would be a sensible strategy.

### Experimental

The starting material for this work was described on pp 110-112 (both Hu Asp2L STM and cdk5 control medium). Twenty ml aliquots of each CM sample were dialyzed against 25mM Tris-HCl (pH 8.0) O/W @ 4°C. A slight amount of ppt was noted following dialysis so the protein content of the dialysate was quantified before and after centrifugation (Boehrman, 15')

<u>Sample</u>	<u>A<sup>280</sup> / ml</u>	<u>µg/ml</u>	<u>total µg</u>	<u>Δ</u>
BUES Asp2L STM CM-dialysate	0.136	0.18	4,050	
" " - Super	0.121	0.16	3,600	450 µg
BUES-cdk5 CM-dialysate	0.122	0.16	4,000	
" " - Super	0.118	0.15	3,750	250 µg

The clarified supernatant obtained following dialysis/centrifugation was chromatographed on a Mono Q column under the following conditions:

- Load ~ 22ml @ 1.0 ml/min w/ 25mM TRIS-HCl (8.0)
- Wash w/ 25mM TRIS-HCl (8.0) until A<sup>280</sup> reduced (to ~ 30%, never reached 0)
- Elute w/ a 30' gradient from 0 → 1.0M NaCl in 25mM TRIS-HCl (pH 8.0)
- Elution profile monitored by A<sup>280nm</sup> (0.1 AUFS) & WB of individual fractions.

Read and understood by me

Date

### (ii) Gel/WB Analysis:

Aliquots of various fractions were taken for NuPAGE gel separation & WB analysis. Due to a fraction collector mishap, I lost a good portion of the column fractions between #1  $\rightarrow$  ~17. There was enough to analyze by gels. Also, in the case of the pH 8.0 ppt, the material (in oxidizing protein by difference) was resuspended in 0.45 ml dH<sub>2</sub>O.

Lane	Sample - gel 1	Sample - gel 2
1	CMBES-HuAp2LTM	8
2	dialyzed CMB (pH 8)	9
3	ppt from dialysis	10
4	Vo I	11
5	Vo II	12
6	4	13
7	5	14
8	6	17
9	7	19
10	SDS	STD

16 25  $\mu$ l sample + 6 25  $\mu$ l  
4x LB + 2.5  $\mu$ l DTT  
11 70°C, 10'

Following electrophoresis (200V, ~45'), the gel was electroblotted to PVDF (135V, 90') & immunoreactive material visualized using UP-191-TB #4 as usual (1/1000 delUP191-TB #4 / 1/2500 GXR-AP)

### (iii) Low pH Treatment of Fraction 11

The protein content of #10, #11 & #12 was determined using the BioRad Assay. 8  $\mu$ l of each fraction was run on a 10% NuPAGE gel & visualized by silver staining.

#10	0.22 $\mu$ g/ $\mu$ l	$\times$ ~60 $\mu$ l	$\approx$ 13 $\mu$ g Total
#11	0.29 $\mu$ g/ $\mu$ l	$\times$ ~50 $\mu$ l	$\approx$ 14 $\mu$ g "
#12	0.43 $\mu$ g/ $\mu$ l	$\times$ ~60 $\mu$ l	$\approx$ 26 $\mu$ g "

(220  $\mu$ g)  
(290  $\mu$ g)  
(430  $\mu$ g)  
~940  $\mu$ g

16  $\mu$ l of #11 was mixed w/ 1.6  $\mu$ l 1.0M NaOAc (45) and incubated o/n @ 4°C. This material was then run in duplicate on a 10% NuPAGE gel as usual (reducing) & 1/2 of the gel stained by silver & 1/2 transferred & stained w/ Ab.

Read and understood by me

Date

## Results:

I previously showed a shift in the Mr of immunoreactive Asp2 ATM derived from the conditioned medium of BVES infection upon acid fraction to pH 4.5. Since this material appeared unstable (immunoreactive band ↓ w/ time) I reasoned that it might be better to partially purify the pro-form & activate near the end. For this reason, an aliquot of the BVES CM from Asp2 ATM was exchanged w/ 25 mM TRIS-HCl (pH 8.0), chromatographed on Mono Q & the elution profile monitored by A<sub>280</sub> absorbance & WB analysis.


Dialysis of the CM caused minor ppt of protein (~10%) & the clarified super was fractionated by Dionion exchange chromatography. A considerable amount of material did not bind to the column & there was no detectable immunoreactive material in the V<sub>0</sub>. Gradient elution with a steep NaCl gradient (0 → 1.0 M, 30') resolved multiple A<sub>280</sub> peaks that eluted between 0 → 0.5 M NaCl. WB analysis of these fractions revealed a strong concentration of immunoreactive material in the expected Mr in fractions 0.11 >> 0.12, well separated from the bulk of the A<sub>280</sub> absorbing impurities. (Note that a shallower gradient might improve the resolution). This immunoreactive material corresponded w/ a A<sub>280</sub> peak eluting @ ~ 0.3 M NaCl.

Gel analysis of the immunoreactive fractions & silver staining revealed a relatively simple pattern of polypeptides & it was clear from comparison with the loading blot of the same fractions that which band corresponded (intensity & position, Mr). In an attempt to reproduce the observation of activation in the acid fraction of the CM, fraction #11 (an aliquot) was incubated @ pH 4.5 on ice & the products visualized by both silver stain & WB. The silver stained gel showed a smear, rather than a discrete band, in both #11 & #11, pH 4.5 & a number of additional changes. Alternatively, the Western blot showed a discrete reduction in the observed Mr of the pH 4.5 treated sample, consistent w/ removal of the NH<sub>2</sub>-terminal prosegment.

Read and understood by me

Date

AP Western blots of Baculovirus clones  
Probed UP-191 (Asp2) TB#4@1:1000



#2's → Scale up



# Exhibit J

# TF High Fives w/ Asp2 ATM & Asp2 ATM His / pLZ

These constructs were made by cutting pVH1393 ATM & ATM His w/ Bam & Not (See p. 87-90) & inserting into pLZ/V5-HIS not using vector V5 or His

High fives (HS) have been in culture in SF High Five media + Gentamycin for 6 passages & are behaving nicely

Dislodge cells into media, pipet vigorously & count.  
Seed  $\sim 2 \times 10^4$  cells / 150mm dish

- Plate 1 dish for each of 3 transient time points (24, 48 hr, 5 day) and 2 for Stables // Construct plus liposome only

- Rock gently for  $\sim 3$  mins - let cells attach for  $\sim 20$  min

- Prepare TF Inoculum: 1 ml SF media

5  $\mu$ l 10  $\mu$ g DNA ATM & ATM His } for each  
20  $\mu$ l ulrasection plus } 60mm plate

Vortex 10 sec, Set at rt  $\sim 15$  mins.

- Remove media from plates - Add DNA/liposomes dropwise.

Rock @ rt (2/min) for 4 1/2 hrs


- Add 2ml SF media  $\rightarrow$  incub w/ wet paper towels in Sealed bag

- Harvest 24 hr time points - pipet cells into media to loosen. Spin 1.5K 5 mins to pellet the cells. Harvest the culture media & cells separately. Store @  $-20^\circ\text{C}$

- Harvest 48 hr time points as above.

- Add Zeocin selection to Stables: remove media from 2x60mm dishes for each construct. Resuspend in 10 ml SF media no antibiotic. Transfer to 150mm dishes. Allow the cells to wait down  $\sim 30$  min rt. Remove media & replace w/ SF media + 400  $\mu$ g/ml Zeocin

Read and understood by me



date

- Harvest 4 1/2 day (108 hr) time points
- Run a 4-12% NuPAGE w/ 26  $\mu$ l media (from 3 times / 2 constructs)
- 10  $\mu$ l 4X NuPAGE SB
- 4  $\mu$ l reductant

Stain w/ colloidal blue  $\rightarrow$  no bands in media only control  
 (the conditioned media from all samples show a ladder of bands - one of the darkest bands in the samples is one that seems to intensify with time is running @ 52 kDa - Western is in mind)

- Refeed Selection plates - mass killing evident

Run sample gel exactly as above. Electrobolt 1 hr. Probe PVDF membrane w/ UPI91 (Asp2) @ 1:1000. Develop via AP.

The 52 kDa band is positive!!! Silver stain of the transferred gel shows uneven transfer. The His-tagged versions seem to be expressing very well but 108 hrs is the best of the 3 time points.

Refeed Zeocin selection plates

Refeed Zeocin  $\rightarrow$  pockets of adherent cells evident  
 HTB refeed once while I was gone. There are thousands of sparsely placed single cells attached all over the plates - no foci evident. (Val Ruff 04.7252 is doing a stable transfection in parallel & sees the same thing - even on her liposome (no DNA) plates)  
 $\therefore$  I think we may not have achieved complete killing of <sup>non</sup>resistant cells  $\therefore$  Split 1:2  $\rightarrow$  400  $\mu$ g/ml Zeo  
 $\rightarrow$  600  $\mu$ g/ml Zeo

Floating cells in both 400 & 600 cultures refeed w/ respective media

On advice from Invitrogen tech. rep. remove selection & allow foci to form.

Add 25 media w/o antibiotic to selection dishes  
 Toss dishes

Read and understood by me

# Large Scale Transient High Five Transfection

Plate 5 x 100mm dishes for each construct: p12 Asp2 $\Delta$ TM  
p12 Asp2 $\Delta$ TMHIS

Cells:  $6 \times 10^6$  / dish

media: 3ml SF media + gentamycin

DNA: 30 $\mu$ g ( $\Delta$ TM &  $\Delta$ TMHIS)

Insectin Plus: 60 $\mu$ l

Plate cells, rock 3 min. let cells attach for ~20mins

Combine media + DNA + liposomes vortex. Inc @ r.t. 15min

Add dropwise to plates. Rock 2 rpm 4 hrs

Add 1ml SF media. Store @ r.t. on wet paper towels. MTB to harvest @ 4 1/2 days.

Mike & Monica report tons of protein is being expressed & secreted into the media.

## 2nd Large Scale Transient

Scale up to 150mm dishes X20 ( $\sim 4 \times 10^7$  cells / confluent T150)

cells:  $1.2 \times 10^7$

media: 12ml SF media + gentamycin (1ml for transfection)

DNA: 60 $\mu$ g (Asp2 $\Delta$ TMHIS)

liposomes: 120 $\mu$ l Insectin Plus

Still dividing & happy

⇒ Put 250 $\mu$ g/ml Zea on one of the 150mm dishes (to select Stables).

Refeed w/ 250 $\mu$ g/ml Zea

Harvest + 250ml transient conditioned media → Monica for purification

Monica reports  $\beta$ -secretase substrate activity -

Read and understood by me

Date

